MITOCHONDRIAL DELIVERY OF RECOMBINANT NUCLEIC ACIDS
20190382794 ยท 2019-12-19
Assignee
Inventors
Cpc classification
C12N2710/16133
CHEMISTRY; METALLURGY
C12N7/00
CHEMISTRY; METALLURGY
A61P7/00
HUMAN NECESSITIES
C12N2710/16122
CHEMISTRY; METALLURGY
A61K48/00
HUMAN NECESSITIES
A61P43/00
HUMAN NECESSITIES
C12N2320/32
CHEMISTRY; METALLURGY
C12N15/111
CHEMISTRY; METALLURGY
A61P25/28
HUMAN NECESSITIES
C12N2810/10
CHEMISTRY; METALLURGY
International classification
Abstract
The present disclosure describes a nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus 2.7 RNA, wherein each subdomain is capable of localization within the mitochondria, for transport into mitochondria. Disclosed herein are also methods of enhancing mitochondrial gene function, or suppressing defective mitochondrial gene function, or both, as well as methods of treating a mitochondrial disorder.
Claims
1. A nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus 2.7 RNA, wherein each subdomain is capable of localization within the mitochondria.
2. The nucleic acid delivery construct of claim 1, wherein the RNA sequences from human cytomegalovirus 2.7 RNA has a sequence identity of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of one or more of the RNA sequences selected from the group consisting of 2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of 2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of 2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) 2.7 RNA, domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA and combinations thereof.
3. The nucleic acid delivery construct of claim 1, wherein the RNA sequences from human cytomegalovirus 2.7 RNA are selected from the group consisting of 2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of 2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of 2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) of 2.7 RNA, domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA and combinations thereof.
4. The nucleic acid delivery construct of claim 3, wherein the one, or two, or three, or four, or more RNA sequences from human cytomegalovirus 2.7 RNA comprise sequences selected from the group consisting of the full length sequence of 2.7 RNA (SEQ ID NO: 1 (sense)), the full length sequence of 2.7 RNA (SEQ ID NO: 2 (antisense)), domain 1 of 2.7 RNA (SEQ ID NO: 3 (sense)), domain 1 of 2.7 RNA (SEQ ID NO: 7 (antisense)), domain 2 of 2.7 RNA (SEQ ID NO: 4 (sense)), domain 2 of 2.7 RNA (SEQ ID NO: 8 (antisense)), domain 3 of 2.7 RNA (SEQ ID NO: 5 (sense)), domain 3 of 2.7 RNA (SEQ ID NO: 9 (antisense)), domain 4 of 2.7 RNA (SEQ ID NO: 6 (sense)), and domain 4 of 2.7 RNA (SEQ ID NO: 10 (antisense)).
5. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus 2.7 RNA comprises domain 2, domain 3 and domain 4 of 2.7 RNA (SEQ ID NO: 11 (sense) or SEQ ID NO: 39 (antisense)); or domain 1, domain 3 and domain 4 of 2.7 RNA (SEQ ID NO: 12 (sense) or SEQ ID NO: 40 (antisense)); or domain 1, domain 2 and domain 4 of 2.7 RNA (SEQ ID NO: 13 (sense) or SEQ ID NO: 41 (antisense)); or domain 1, domain 2 and domain 3 of 2.7 RNA (SEQ ID NO: 14 (sense) or SEQ ID NO: 42 (antisense)).
6. The nucleic acid delivery construct of claim 1, wherein the nucleic acid delivery construct comprises at least one spacer sequences.
7. The nucleic acid delivery construct of claim 6, wherein if the nucleic acid delivery construct comprises at least two spacer sequences, at least one spacer sequence is at the 5 end and at least one another spacer sequence is at the 3 end of the RNA sequence from human cytomegalovirus 2.7 RNA.
8. The nucleic acid delivery construct of any of claim 6, wherein the at least one spacer sequence is selected from the group consisting of S la (SEQ ID NO:26), S1b (SEQ ID NO:27), S2a (SEQ ID NO:28), S2b (SEQ ID NO:29), S3a (SEQ ID NO:30), S3b (SEQ ID NO:31), S4a (SEQ ID NO:32), S4b (SEQ ID NO:33), Sha (SEQ ID NO:34), S6b (SEQ ID NO:35), S8a (SEQ ID NO:36), S8b (SEQ ID NO:37) and Spacer F3A (SEQ ID NO: 38); and/or optionally, wherein the spacer sequence comprises a stop codon.
9. The nucleic acid delivery construct of claim 3, wherein each RNA sequence is selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2 SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA, according to formula I: ##STR00001## wherein each Xis independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein each X is optionally preceded or followed or flanked by at least one or more spacer sequences as defined in claims 6 to 8.
10. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus 2.7 RNA is a tetramer of a RNA sequences, wherein each RNA sequence is selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2 SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA, according to formula II: ##STR00002## wherein each Xis independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined in claim 8.
11. The nucleic acid delivery construct of claim 10, wherein each X is D2 (SEQ ID NO: 4 or SEQ ID NO: 8); or wherein each X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9); or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 15 or SEQ ID NO: 51 or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 16 or SEQ ID NO: 52.
12. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus 2.7 RNA is an octamer of a RNA sequences selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA, according to formula III: ##STR00003## wherein X and Y are different from each other, wherein each X and each Y are independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined in claim 8.
13. The nucleic acid delivery construct of claim 12, wherein X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9) and Y is D2 (SEQ ID NO: 4 or SEQ ID NO: 8); or wherein X is D2 (SEQ ID NO: 4 or SEQ ID NO: 8) and Y is D3 (SEQ ID NO: 5 or SEQ ID NO: 9); or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 17 or SEQ ID NO: 53; or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 18.
14. The nucleic acid delivery construct of claim 3, wherein the RNA sequence from human cytomegalovirus 2.7 RNA is an octamer of a RNA sequences selected from the group consisting of domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7), domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8), domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) and domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA, according to formula IV: ##STR00004## wherein X and Y are different from each other, wherein each X and each Y are independently selected from the group consisting of D1 (SEQ ID NO: 3 or SEQ ID NO: 7), D2 (SEQ ID NO: 4 or SEQ ID NO: 8), D3 (SEQ ID NO: 5 or SEQ ID NO: 9), D4 (SEQ ID NO: 6 or SEQ ID NO: 10) or combinations thereof, including duplicates, triplicates, quadruplicates, quintuplicates, sextuplicates, septuplicates, octuplicates, or longer repeats of single domains; and wherein the spacer sequences S1a, S1b, S2a, S2b, S3a, S3b S4a and S4b are as defined in claim 8.
15. The nucleic acid delivery construct of claim 14, wherein X is D3 (SEQ ID NO: 5 or SEQ ID NO: 9) and Y is D2 (SEQ ID NO: 4 or SEQ ID NO: 8); or wherein the nucleic acid delivery construct comprises a nucleic acid sequence according to SEQ ID NO: 19.
16. (canceled)
17. (canceled)
18. A vector, a recombinant cell, or a recombinant organism comprising the nucleic acid sequence of claim 1.
19. (canceled)
20. A nucleic acid sequence comprising at least one or more sense or antisense RNA sequences of the human cytomegalovirus 2.7 RNA selected from group consisting of domain 1 (D1; SEQ ID NO: 3 or 7), domain 2 (D2; SEQ ID NO: 4 or 8), domain 3 (D3; SEQ ID NO: 5 or 9) and domain 4 (D4; SEQ ID NO: 6 or 10).
21. A method of enhancing mitochondrial gene function, or suppressing defective mitochondrial gene function, or both (provided that in this case the mitochondrial genes are different from each other), the method comprising administering to a subject the nucleic acid delivery construct according to claim 1, wherein the mitochondrial gene functions are different from each other.
22. A method of treating a mitochondrial disorder, the method comprising administering to a subject the nucleic acid delivery construct according to claim 1.
23. (canceled)
24. The method according to claim 22, wherein the mitochondrial disorder is selected from the group consisting of maternally inherited diabetes mellitus, Leber's hereditary optic neuropathy (LHON), neuropathy, ataxia, retinitis pigmentosa, myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial myopathy encephalopathy lactic acidosis and stroke like symptoms (MELAS), Parkinson's disease, chronic obstructive pulmonary disorder (COPD), Kearns-Sayre Syndrome (KSS), Pearson Syndrome and progressive opthalmoplegia (PEO).
25. (canceled)
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:
[0010]
[0011]
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
DEFINITION OF TERMS
[0031] The term naked nucleic acid refers to a nucleic acid (either DNA or RNA) that is, as opposed to non-viral or viral vectors, not complexed with any other compound neither with histones, proteins, lipids, sugars, nanoparticular structures, viral capsids or envelopes nucleic acid that occurs, for example, during cell to cell transfer or transformation of cells with nucleic acid sequences.
[0032] The term coding/non-coding nucleic acid sequences refers to both coding and non-coding nucleic acid sequences. A non-coding nucleic acid (that is for example RNA or DNA) is a nucleic acid molecule that is not translated into a protein. Conversely, a coding nucleic acid molecule is a nucleic acid molecule that is translated into a protein. For example, when used in regards to RNA, these non-coding RNA are also termed non-protein-coding RNA (npcRNA), non-messenger RNA (nmRNA) and functional RNA (fRNA). For example, a DNA sequence from which a functional, non-coding RNA is transcribed is often known as an RNA gene. Examples of non-coding RNA genes include, but are not limited to, highly abundant and functionally important RNAs such as, for example, transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), as well as RNAs such as small nucleolar RNAs (snoRNAs), microRNAs, small interfering RNAs (siRNAs), antisense RNAs (asRNA), small nuclear RNAs (snRNA or U-RNA), exosomal/extracellular RNAs (exRNAs), Piwi-interacting RNAs (piRNA), small Cajal body RNA genes (scaRNAs) and long non-coding RNAs (ncRNAs or lncRNAs), which include examples such as, but not limited to, X-inactive specific transcript (Xist) and HOX transcript antisense RNA (HOTAIR). The number of non-coding RNAs encoded within the human genome is unknown; however, transcriptomic and bioinformatic studies suggest the existence of thousands of non-coding RNAs. Since many of the newly identified non-coding RNAs have not been validated for their function, it is possible that many are non-functional. It is also likely that many non-coding RNAs are non-functional (often termed junk RNA), and are the result of spurious transcription.
[0033] The term sense and antisense refers to concepts used to compare the polarity of nucleic acid molecules, such as DNA or RNA, to other nucleic acid molecules. Depending on the context, these sense and antisense molecules may refer to different molecules compared to the common 5-3 naming convention for nucleic acid sequences. For example, in double stranded DNA (dsDNA), a single strand of DNA may be called the sense strand (or positive (+) strand), if the RNA version of the same sequence is translated or translatable into proteins. The complementary strand to this positive DNA strand is called the antisense (or negative () strand). This is not to be confused with the concept of coding and non-coding nucleic acid sequences, as defined above. As an example, the two complementary strands of double-stranded DNA (dsDNA) are usually differentiated as the sense strand and the antisense strand. The DNA sense strand looks like the messenger RNA (mRNA) and can be used to read the expected protein code; for example, ATG in the sense DNA may correspond to an AUG codon in the mRNA, encoding the amino acid methionine. However, the DNA sense strand itself is not used to make protein by the cell. It is the DNA antisense strand which serves as the source for the protein code, because, with bases complementary to the DNA sense strand, it is used as a template for the mRNA. Since transcription results in an RNA product complementary to the DNA template strand, the mRNA is complementary to the DNA antisense strand. The mRNA is what is used for translation (protein synthesis). In an example for RNA, antisense RNA is an RNA sequence (or transcript) that is complementary to endogenous mRNA. In other words, it is a non-coding strand complementary to the coding sequence of RNA. Introducing a transgene coding for antisense RNA is, for example, a technique used to block expression of a gene of interest.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
[0034] Mitochondria, a double membrane-bound organelle found in all eukaryotic organisms, are typically associated with ATP production in all living eukaryotic cells. However, defects in enzymes that form part of the respiratory cycle result in, for example, mitochondria-associated diseases, which can be difficult to treat due to the inaccessibility of the mitochondrial genome. Therefore, in order to treat such diseases associated with, for example, defects in the mitochondrial genome, the present disclosure identifies subdomains and combinations of RNA sequences within, for example, the human cytomegalovirus (CMV) 2.7 RNA for targeted delivery of RNA into mitochondria, using the propensity the human cytomegalovirus 2.7 RNA for targeting and co-localising into mitochondria. Thus, disclosed herein is the mitochondrial delivery of a recombinant coding RNA into the mitochondria, which leads to, for example recombinant mitochondrial gene expression. Also disclosed herein is the mitochondrial delivery of, for example, a non-coding antisense RNA into the mitochondria, which triggers functional knockdown of mitochondrial gene expression. The identified sequences are for use in gene therapy to, for example, suppress mitochondrial malfunction, or to restore mitochondrial gene functions in neurodegenerative, or other mitochondria-associated diseases, or for anti-ageing purposes.
[0035] It was shown that the 5 terminal part of the human cytomegalovirus 2.7 RNA, the so-called p137 RNA, co-localizes with mitochondrial complex I protecting complex I activity, however, functional coding or non-coding RNA has not yet being delivered using the 2.7 RNA sequences. The generation of a vector system that allows delivering recombinant nucleic acids into the mitochondria allow for, for example the genetic therapy of mitochondria-associated, yet incurable, human diseases. The distinct non-coding RNA originating from the human cytomegalovirus, the so called 2.7 RNA, was found to localize to the mitochondria of mammalian cells and bind to mitochondrial complex I. Thus, in one example, the nucleic acid delivery system as disclosed herein comprises RNA, or DNA, or combinations thereof. In another example, the nucleic acid delivery system comprises RNA. In another example, the nucleic acid delivery system comprises DNA.
[0036] Thus, in one example, the present invention refers to a nucleic acid delivery construct comprising at least one sense or antisense RNA subdomain of the human cytomegalovirus 2.7 RNA, wherein each subdomain is capable of localisation within the mitochondria. In another example, the nucleic acid delivery construct comprises at least one sense RNA subdomain of the human cytomegalovirus 2.7 RNA. In another example, the nucleic acid delivery construct comprises at least one antisense RNA subdomain of the human cytomegalovirus 2.7 RNA. In yet another example, the nucleic acid delivery construct comprises one or more sense or antisense RNA subdomains of the human cytomegalovirus 2.7 RNA.
[0037] The nucleic acid delivery construct, as disclosed herein, can comprise a number of sense or antisense RNA subdomains. In one example, the number of subdomains in the nucleic acid delivery construct is, but is not limited to, between 1 to 10 subdomains, between 5 to 15 subdomains, between 12 to 22 subdomains, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 subdomains. In other words, a nucleic acid delivery construct according to the present disclosure comprises between 1 to 10 RNA sequences, between 5 to 15 RNA sequences, between 12 to 22 RNA sequences, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 RNA sequences.
[0038] The present disclosure relates to the identification of RNA sequences within CMV 2.7 RNA for targeted delivery into mitochondria. That is to say that the human cytomegalovirus 2.7 RNA, when introduced to a cell, seeks out and enters the mitochondria, and, as a result, is not found in the cytoplasm of said cell. The same can be said for each of the RNA subdomains of the human cytomegalovirus 2.7 RNA. The identified RNA sequences consist of four thermodynamically conserved structural sub-domains (D1 to D4). From these sub-domains, tandem repeats and combinations of RNA sequences are constructed. Tandem repeats constructed from functionally relevant domains, for example domain 2 (D2X4) and domain 3 (D3X4), among which, for example, domain 3 (D3X4), exhibits enhanced mitochondrial localization potential. Combination of tandem repeats are constructed as, for example, (D3X4_D2X4 or D2X4_D3X4), in which (D3X4_D2X4) exhibits highest mitochondrial targeting potential. Domain 1 and 4 exhibit similar structures on the antisense transcript and the antisense domains AS1 and AS4 exhibit substantial mitochondrial localization potential. Delivery of CMV 2.7 RNA-derived sequences with coding RNA into mitochondria leads to recombinant mitochondrial gene expression. For example, the dual tetrameric of domains D3 and D2 (D3x4_D2x4) protects mitochondrial complex I with higher efficiency than the wild type 2.7 RNA.
[0039] Thus, in one example, the nucleic acid sequence is as disclosed herein, wherein each subdomain is capable of localisation within the mitochondria but does not localise into the cytoplasm.
[0040] Disclosed herein are isolated RNA sequences of the human cytomegalovirus p137 RNA, which is the 5 terminal end of the human cytomegalovirus 2.7 RNA. This 5 terminal end of the human cytomegalovirus 2.7 RNA sequences comprises of four, thermodynamically conserved, structural subdomains, named D1 to D4, respectively, each of which is capable of targeting the mitochondria of a cell. Thus, in one example, the nucleic acid delivery construct, as disclosed herein, comprises RNA sequences from human cytomegalovirus 2.7 RNA, which are, but are not limited to, 2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of 2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of 2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) of 2.7 RNA, domain 4 (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA and combinations thereof. In one example, the nucleic acid delivery construct comprises one type of RNA sequence as disclosed herein. Examples of types of RNA sequences are, but are not limited to, sense RNA, antisense RNA, messenger RNA (mRNA), transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snRNA), Piwi-interacting RNA (piRNA), tRNA-derived RNA (tsRNA), small rDNA-derived RNA (srRNA), ribosomal RNA (rRNA), long non-coding RNA (lncRNA), short hairpin RNA (shRNA) and transfer-messenger RNA (tmRNA). In one example, the nucleic acid delivery construct comprises sense RNA. In another example, the nucleic acid delivery construct comprises antisense RNA. In a further example, the nucleic acid delivery construct comprises a combination of sense and antisense RNA. In another example, the nucleic acid delivery construct comprises a combination of the RNA sequences as disclosed herein. In yet another example, the nucleic acid delivery construct comprises a combination of the RNA sequences as disclosed herein, wherein the nucleic acid delivery construct can comprise multiple repeats of a single RNA sequence. In another example, the nucleic acid delivery construct comprises the full length sequence of 2.7 RNA (SEQ ID NO: 1 (sense)). In another example, the nucleic acid delivery construct comprises the full length sequence of 2.7 RNA (SEQ ID NO: 2 (antisense)). In yet another example, the nucleic acid delivery construct comprises domain 1 of 2.7 RNA (SEQ ID NO: 3 (sense). In yet another example, the nucleic acid delivery construct comprises domain 1 of 2.7 RNA (SEQ ID NO: 7 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 2 of 2.7 RNA (SEQ ID NO: 4 (sense)). In one example, the nucleic acid delivery construct comprises domain 2 of 2.7 RNA (SEQ ID NO: 8 (antisense)). In another example, the nucleic acid delivery construct comprises domain 3 of 2.7 RNA (SEQ ID NO: 5 (sense)). In yet another example, the nucleic acid delivery construct comprises domain 3 of 2.7 RNA (SEQ ID NO: 9 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 4 of 2.7 RNA (SEQ ID NO: 6 (sense)). In one example, the nucleic acid delivery construct comprises domain 4 of 2.7 RNA (SEQ ID NO: 10 (antisense)). In another example, the nucleic acid delivery construct comprises domain 2, domain 3 and domain 4 of 2.7 RNA (SEQ ID NO: 11 (sense) or SEQ ID NO: 39 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 1, domain 3 and domain 4 of 2.7 RNA (SEQ ID NO: 12 (sense) or SEQ ID NO: 40 (antisense)). In a further example, the nucleic acid delivery construct comprises domain 1, domain 2 and domain 4 of 2.7 RNA (SEQ ID NO: 13 (sense) or SEQ ID NO: 41 (antisense)). In another example, the nucleic acid delivery construct comprises domain 1, domain 2 and domain 3 of 2.7 RNA (SEQ ID NO: 14 (sense) or SEQ ID NO: 42 (antisense)).
[0041] As used herein, the term sequence identity refers to the situation where two polynucleotide or amino acid sequences are identical, or have a number of identical residues (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window. The term percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms sequence identity, as used herein, denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid may comprise a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24 to 48 nucleotide (8 to 16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence, which may include deletions or additions, which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence. Thus, in another example, the nucleic acid delivery system, as disclosed herein, comprises RNA sequences from human cytomegalovirus 2.7 RNA, wherein the RNA sequences have a sequence identity of between 70% to 99%, of between 75% to 85%, of between 78% to 88%, of between 80% to 89%, of about 90%, of about 91%, of about 92%, of about 93%, of about 94%, of about 95%, of about 96%, of about 97%, of about 98%, or of about 99% of one or more of the RNA sequences disclosed herein. In one example, the nucleic acid delivery construct is as disclosed herein, wherein the RNA sequences from human cytomegalovirus 2.7 RNA has a sequence identity of about 90%, of about 91%, of about 92%, of about 93%, of about 94%, of about 95%, of about 96%, of about 97%, of about 98%, or of about 99% of one or more of the RNA sequences, which are, but are not limited to, 2.7 RNA (SEQ ID NO: 1 or SEQ ID NO: 2), domain 1 (D1; SEQ ID NO: 3 or SEQ ID NO: 7) of 2.7 RNA, domain 2 (D2; SEQ ID NO: 4 or SEQ ID NO: 8) of 2.7 RNA, domain 3 (D3; SEQ ID NO: 5 or SEQ ID NO: 9) 2.7 RNA, domain (D4; SEQ ID NO: 6 or SEQ ID NO: 10) of 2.7 RNA and combinations thereof.
[0042] The nucleic acid delivery constructs, as disclosed herein, can also further include one or more changes in the nucleic acid sequence. In one example, such a change is a mutation in the RNA sequence. In another example, the nucleic acid delivery construct comprises one or more non-structural mutations. In yet another example, the nucleic acid delivery construct comprises one or more structure neutral mutations. As used herein, the term non-structural mutation or structure neutral mutation refers to a mutation in a nucleic acid sequence which changes the sequence of the nucleic acid sequence, but preserves the functional structure of the mutated sequence compared to the unmutated sequence.
[0043] From these subdomains, tandem repeats and combinations of RNA sequences are constructed. As used herein, the term tandem repeats refers to sections within a nucleic acid sequence where a pattern of one or more nucleotides is repeated and the repetitions are directly adjacent to each other. For example, a sequence of ATGGC repeated 3 times in a row, thus resulting in a sequence comprising ATGGC ATGGC ATGGC, is understood to be a tandem repeat. Based on the invention as disclosed herein, sequences are constructed from functional RNA domains, that is from any of the subdomains D1, D2, D3 or D4. Examples of such constructed domains are, but are not limited to, domain 2 (a four-time repeat of domain 2, in other words D2X4) and domain 3 (a four-time repeat of domain 3, in other words D3X4). Thus, in one example, the nucleic acid delivery system as disclosed herein comprises combinations and/or multiples of the RNA sequences disclosed herein, including, but not limited to, duplicates (2), triplicates (3), quadruplicates (4), quintuplicates (5), sextuplicates (6), septuplicates (7) octuplicates (8) or longer repeats of single domains. In other words, the combinations and/or multiples of the RNA sequences disclosed herein include, but are not limited to, dimers, trimers, tetramers, or polymers of single domains.
[0044] As used herein, the term spacer refers to a sequence of nucleic acids that are inserted at either the 5 or 3 end of a nucleic acid sequence, or at both ends of a nucleic acid sequence, within a construct. The spacer is inserted at defined positions within the nucleic acid sequence in order to ensure that the structural integrity of a nucleic acid sequence, for example in an RNA sequence, remains. This ensures the retention of function or characteristic of the RNA sequence, for example, the mitochondrial targeting capability of the nucleic acid construct. The spacer also functions to prevent any steric effects from occurring and to enable the nucleic acid sequence to attain its natural tertiary structure, thereby also facilitating the retention of its function. Thus, in one example, the nucleic acid delivery construct as disclosed herein comprises between 1 to 10, between 5 to 15, between 8 to 24, at least one, at least two, at least three, at least four, at least 5, about 6, about 7, about 8 or about 9 spacer sequences. In one example, the nucleic acid delivery construct comprises about 6 spacer sequences. In another example, the nucleic acid delivery construct comprises about 7 spacer sequences. In yet another example, the nucleic acid delivery construct comprises about 8 spacer sequences. In a further example, the nucleic acid delivery construct comprises about 9 spacer sequences.
[0045] As stated above, the spacers sequences can be placed anywhere within the nucleic acid sequence. For example, spacers can found at the beginning (that is the 5 end) of an RNA sequence. Spacers can also be found at the end (that is the 3 end) of an RNA sequence. When more than one spacer is used, these spacers can also be found at both the 5 and 3 ends of an RNA sequence. Thus, in one example, when the nucleic acid delivery construct comprises at least two or more spacers, at least one spacer sequence is at the 5 end and at least one other spacer sequence is at the 3 end of the RNA sequence of human cytomegalovirus 2.7 RNA.
[0046] The length of a spacer is defined, for example, by the specific function that the spacer is intended to fulfil. For example, if the function of a spacer is to prevent steric hindrance between two or more RNA sequences, this spacer could then be between tens to hundreds of nucleotides long, depending on the size of the resulting RNA structure. In other words, the spacer sequence disclosed in the present invention is sufficiently long to prevent any steric hindrance from arising between neighbouring RNA subdomains and/or wherein the length of the spacer sequence is sufficiently long to allow neighbouring RNA subdomains to fold into their thermodynamically preferred structure. Having said that, a person skilled in the art would appreciate that the spacer length is dependent on the length, structure, and combination(s) of the at least one sense or antisense RNA subdomains as disclosed in the nucleic acid delivery system disclosed herein. In one example, the spacer sequence is between 5 to 40 nucleotides, between 5 to 30 nucleotides, between 6 to 10 nucleotides, between 8 to 14 nucleotides, between 15 to 20 nucleotides, between 22 to 28 nucleotides, between 25 to 37, between 28 to 39 nucleotides, about 7 nucleotides, about 9 nucleotides, about 11 nucleotides, about 12 nucleotides, about 13 nucleotides, about 15 nucleotides, about 17 nucleotides, about 21 nucleotides, about 27 nucleotides, about 29 nucleotides, about 30 nucleotides, about 34 nucleotides, about 36 nucleotides in length. In one example, the spacer sequence is 5 nucleotides long. In another example, the spacer sequence is 6 nucleotides long. In yet another example, the spacer sequence is 13 nucleotides long. In a further example, the spacer sequence is 17 nucleotides long. In one example, the spacer sequence is 24 nucleotides long. In yet another example, the spacer sequence is 32 nucleotides long.
[0047] In one example, the spacer sequence is, but is not limited to S1a (SEQ ID NO:26), S1b (SEQ ID NO:27), S2a (SEQ ID NO:28), S2b (SEQ ID NO:29), S3a (SEQ ID NO:30), S3b (SEQ ID NO:31), S4a (SEQ ID NO:32), S4b (SEQ ID NO:33), Sha (SEQ ID NO:34), S6b (SEQ ID NO:35), S8a (SEQ ID NO:36), S8b (SEQ ID NO:37) and Spacer F3A (SEQ ID NO: 38), and combinations thereof.
[0048] Spacer sequences may also contain functional nucleic acid sequences, or other structural or functional motifs. For example, a spacer sequence can further optionally comprise a stop codon.
[0049] As used herein, the term nuclear localization signal or NLS refers to nucleic acid sequences coding for one or more additional secretory signals or signalling peptides. These nuclear localization sequences can be added to the 5 or 3 end of the nucleic acid sequence, thereby resulting in the expression of such a nuclear localization sequence at the C-terminus or N-terminus or both the C- and N-termini of a peptide. One example known in the art is the addition of a nuclear localisation sequence (NLS) which directs the nascent protein for import from the cytoplasm into to the nucleus of the cell. There are many different versions of nuclear localisation sequences and their length and composition is dependent on the cell type from which they have been isolated. For example, the nuclear localisation sequence of nucleoplasmin is AVKRPAATKKAGQAKKKKLD, whereas the nuclear localisation sequence of c-myc is PAAKRVKLD. Thus, in one example, the nucleic acid delivery construct further optionally comprises a nuclear localization signal (NLS).
[0050] In one example, the nucleic acid delivery system disclosed herein is a RNA sequence according to the formula I shown in
[0052] In one example, the nucleic acid delivery system disclosed herein is a RNA sequence according to the formula II shown in
[0054] In one example, the nucleic acid delivery system disclosed herein is a RNA sequence according to the formula III shown in
[0056] In one example, the nucleic acid delivery system disclosed herein is an octamer of RNA sequences according to the formula IV shown in
[0058] In order for the claimed nucleic acid delivery system to function as a delivery system, the nucleic acid sequence needs to further comprise a payload. As used herein, the term payload refers to one or more nucleic acid sequences that can be inserted into the sequence of the nucleic acid delivery system, which, as a result of its insertion, then acts on or within the mitochondria of the cell. A payload can be, but is not limited to, a recombinant nucleic acid sequence, RNA, DNA, modified nucleic acids, nucleic acid analogues and nucleic acid mimics including pyranosyl nucleic acids (p-RNA), threose nucleic acids (TNA), glycol nucleic acids (GNA), peptide nucleic acids (PNA), alanyl nucleic acids (ANA), locked nucleic acids (LNA), morpholinophosphoramidates (MF), non-nucleic acid-based molecules including peptides, proteins, lipids, carbohydrates, synthetic polymers, small molecular weight compounds, and the like. In one example, the recombinant nucleic acid sequence is, but is not limited to, non-coding nucleic acid sequence, coding nucleic acid sequence, single-stranded nucleic acid sequence, linear double-stranded nucleic acid sequence, antisense nucleic acid sequences, sense nucleic acid sequence circular single-stranded nucleic acid sequence and circular double-stranded nucleic acid sequence. In another example, the recombinant nucleic acid sequence is a complete, natural or recombinant mitochondrial genome. In yet another example, the nucleic acid delivery construct comprises a sequence according to any one of SEQ ID NO: 20 to SEQ ID NO: 82.
[0059] Furthermore, said payload needs to be attached to the nucleic acid delivery system in order to be able to be transported. In one example, the payload is covalently linked to the nucleic acid delivery system. In another example, the payload is non-covalently linked to the nucleic acid delivery system. Non-covalent linkage can be achieved via electrostatic interactions including ionic interactions, hydrogen bonding, or halogen bonding, via Van der Waals forces including dipole-dipole interactions, induced dipole interactions, or London dispersion forces, via -effects including - interactions, cation- or anion- interactions, or polar- interactions, or via hydrophobic effects. A covalent linkage, on the other hand, is a linkage that involves the sharing of electron pairs between atoms. Examples of covalent bonds or linkages include many kinds of interactions including, but not limited to, -bonding, -bonding, metal-to-metal bonding, agostic interactions, bent bonds, and three-centre two-electron bonds.
[0060] Akin to the physical concepts governing, for example, the aeronautical concept of payload transportation, a person skilled in the art would appreciate that the size of a payload dictates the size of the carrier (that is the nucleic acid delivery system) required to carry such a payload to its intended destination. Thus, in one example, the total size of nucleic acid delivery construct is proportional to the size of a payload. This means that a nucleic acid delivery system for a payload of, for example, 200 nucleic acids in length, would be four times larger than a nucleic acid delivery system of a payload which is only 50 nucleic acids long. Conversely, a payload, which is only 10 nucleic acids long, can make use of a nucleic acid delivery system that is half the size of a nucleic acid delivery system for a payload which is 20 nucleic acids long. Thus, in one example, the nucleic acid delivery system is scalable. In another example, the nucleic acid delivery system is scalable according to, or proportionally to, the size of the payload.
[0061] The potential of the most active RNA, (D3)4_(D2)4, to co-deliver the MT-ATP6-directed antisense RNA into the mitochondria was investigated. To this end, the MT-ATP6 antisense RNA was fused to the 5 end of (D3)4_(D2)4 via a spacer, thereby generating the construct ATP6_(D3)4_(D2)4. The spacer was selected to preserve both the open structure of the antisense RNA, as well as the domain structures within (D3)4_(D2)4 according to predictions with mfold (
[0062] Also encompassed in the present disclosure are vectors, recombinant cells, recombinant organisms and nucleic acid sequences, which comprise or express the nucleic acid delivery system as disclosed herein. In one example, a vector comprises the nucleic acid delivery system as disclosed herein. In another example, the vector comprises a naked nucleic acid, or a non-viral vector, or a viral vector, or combinations thereof.
[0063] In one example, a recombinant cell comprises the nucleic acid sequence as disclosed herein. In another example, the recombinant cell expresses the nucleic acid sequence in a consecutive manner (that is, consecutively). In yet another example, the recombinant cell expresses the nucleic acid sequence in a non-consecutive manner (that is, non-consecutively). In one example, a recombinant organism comprises the nucleic acid sequence as disclosed herein. In another example, the recombinant organism expresses the nucleic acid sequence in a consecutive manner (that is, consecutively). In yet another example, the recombinant organism expresses the nucleic acid sequence in a non-consecutive manner (that is, non-consecutively).
[0064] In one example, a nucleic acid sequence comprises at least one or more sense or antisense RNA sequences of the human cytomegalovirus 2.7 RNA. In another example, the RNA sequences of the human cytomegalovirus 2.7 RNA are, but are not limited to, domain 1(D1; SEQ ID NO: 3 or 7), domain 2 (D2; SEQ ID NO: 4 or 8), domain 3 (D3; SEQ ID NO: 5 or 9) and domain 4 (D4; SEQ ID NO: 6 or 10).
[0065] Also disclosed within the scope of the present invention are methods of treating diseases. Mitochondrial disorders are usually caused by heterogeneity resulting from unequal segregation of defective mitochondrial DNA (mDNA). Thus, one therapeutic method is to reduce the abundance of defective messenger RNA (mRNA), thereby allowing the wild type messenger RNA to re-populated the mitochondria. The identified sequences can thus be used in gene therapy to suppress mitochondrial malfunction, or to restore mitochondrial gene functions in neurodegenerative, or other mitochondria-associated diseases, or for anti-aging purposes.
[0066] The parental human cytomegalovirus 2.7 RNA can protect the mitochondrial complex I from certain inhibitors and, thus protect the mitochondria from oxidative stress and DNA damage, thereby increasing cell viability. The parental human cytomegalovirus 2.7 RNA was also found to prevent death of dopaminergic neurons in the brain. The death of dopaminergic neurons in the brain is considered to be a hallmark of Parkinson's disease. It has been shown that, for example, a short 100 nucleotide long subdomain (domain 2 of the 2.7 RNA) successfully protected the mitochondrial complex Ito a similar extent as the parental 2.7 RNA sequences. Therefore, domain 2, among the other domains disclosed herein, can be implemented in the treatment of Parkinson's disease. The term parental sequence refers to the original 2.7 RNA sequence derived from human cytomegalovirus strain towne (GenBank: FJ616285.1).
[0067] Cell penetrating peptides can be used to successfully deliver 2.7 derived sequences into, for example, lung tissue of human and animal models. This delivery serves to treat impaired oxidative phosphorylation (OXPHOS), for example, and in another example, increase reactive oxygen species (ROS) levels associated with chronic obstructive pulmonary disorder (COPD). Additionally, antisense RNA can be used to target hereditary mitochondrial defects in the lungs
[0068] 2.7 RNA, or subdomains thereof, can also be used to deliver intact mitochondrial genomes for treatment of disorders with mitochondrial DNA (mDNA) deletions, such as Kearns-Sayre Syndrome (KSS), Pearson Syndrome and progressive opthalmoplegia (PEO), all of which share overlapping phenotypes and which are associated with a common 4977 base pair deletion within the mitochondrial DNA.
[0069] Thus, in one example, there is disclosed a method of treating a mitochondrial disorder. In another example, the method of treating a mitochondrial disorder comprises administering to a subject the nucleic acid delivery construct as disclosed herein. In yet another example, the method comprises using the nucleic acid delivery construct to deliver antisense RNA. The mitochondrial disorder can be, but is not limited to, maternally inherited diabetes mellitus, Leber's hereditary optic neuropathy (LHON), neuropathy, ataxia, retinitis pigmentosa, myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial myopathy encephalopathy lactic acidosis and stroke like symptoms (MELAS), Parkinson's disease, chronic obstructive pulmonary disorder (COPD), Kearns-Sayre Syndrome (KSS), Pearson Syndrome and progressive opthalmoplegia (PEO).
[0070] Said mitochondrial disorders can be treated in various ways, for example, by targeting one or more mitochondrial genes, which are, but not limited to, MT-TL1 (tRNA leucine), MT-ND1, MT-ND4, MT-ND6, MT-ATP6, MT-TK (tRNA lysine), MT-ND1, MT-NDS, MT-TH (histidine), MT-TL1 (leucine), MT-TV (valine), and combinations thereof.
[0071] One example of the treatment of mitochondrial disorders is the antisense-mediated suppression of defective mitochondrial genes/gene functions. This involves, for example, the use of the nucleic acid delivery system as disclosed herein to deliver antisense RNA into the mitochondria. For example, the ability of the human cytomegalovirus 2.7-mediated delivery of antisense RNA to successfully knock down mt-ATP6 mRNA within mitochondria has been demonstrated in the present application. Defects in the mt-ATP6 have been associated with, for example but not limited to, neuropathy, ataxia, and retinitis pigmentosa (NARP). In the example of NARP, the 2.7-mediated antisense RNA delivery system has been used to successfully knock down defective mRNA associated with NARP, thereby allowing the wild type ATP6 mRNA to re-populate the mitochondria. Hence, the nucleic acid system as disclosed herein can be used for treatment of NARP.
[0072] Another example of how the claimed invention can be used in the treatment of mitochondrial disorders is the delivery of a mitochondrial gene. Alternatively to suppressing defective mRNAs using antisense RNA, the nucleic acid delivery system as disclosed herein can be used to deliver an intact (mitochondrial) gene into the mitochondrial to increase the ratio of intact mRNA to defective RNA. Provided below is a non-exhaustive list of target genes and their associated diseases.
TABLE-US-00001 TABLE 1 A list of target genes and associated diseases. Disease Affected gene Maternally inherited diabetes MT-TL1 (tRNA leucine) mellitus Leber's hereditary optic MT-ND1, MT-ND4, MT-ND6 neuropathy (LHON) Neuropathy, Ataxia and Retinitis MT-ATP6 pigmentosa (NARP) Myoclonic epilepsy with ragged MT-TK (tRNA lysine) red fibres (MERRF) Mitochondrial myopathy MT-ND1, MT-ND5, MT-TH encephalopathy lactic acidosis (histidine), MT-TL1 (leucine), and stroke like symptoms MT-TV (valine). (MELAS) MT-TL1: Mitochondrial encoded tRNA leucine; MT- TV: Mitochondrial encoded tRNA valine; MT-TK: Mitochondrial encoded tRNA lysine; MT-TH: Mitochondrial encoded tRNA histidine; MT-ND1: Mitochondrial encoded NADH dehydrogenase 1; MT-ND4: Mitochondrial encoded NADH dehydrogenase 1; MT-ND5: Mitochondrial encoded NADH dehydrogenase 5; MT-ND6: Mitochondrial encoded NADH dehydrogenase 6; MT-ATP6: Mitochondrial encoded ATP synthase 6.
[0073] Yet another example of the treatment of mitochondrial disorders is a combination of both suppressing defective mitochondrial gene function and the delivery of intact genes into the mitochondria to increase the ratio between intact and defective genes.
[0074] As disclosed herein, a therapeutic application of the invention can be either the delivery of antisense sequences to suppress defective gene expression, or, alternatively, to deliver intact genes to complement the correct gene function, or a combination of both.
[0075] Thus in one example, there is disclosed a method of enhancing mitochondrial gene function, or suppressing defective mitochondrial gene function, or both (provided that in this case, the mitochondrial genes are different from each other). In the case of both enhancing mitochondrial gene function and suppressing defective mitochondrial gene function, the enhancing and suppressing of gene function can take place simultaneously or sequentially. In one example, the enhancing and suppressing of gene function takes place simultaneously. In another example, the mitochondrial gene functions are different from each other. In yet another example, the method comprises administering to a subject the nucleic acid delivery sequence as disclosed herein.
[0076] For example, domain 3 (D3X4) is shown to exhibit enhanced mitochondrial localisation potential. Combination of tandem repeats are constructed as, for example, D3X4_D2X4 or D2X4_D3X4, whereby D3X4_D2X4 is shown to exhibit the highest mitochondrial targeting potential. It is further shown that domains 1 and 4 exhibit similar structures on the antisense transcript, and that the antisense domains AS1 and AS4 exhibit substantial mitochondrial localization potential.
[0077] Delivery of CMV 2.7 RNA-derived sequences with coding RNA into mitochondria leads to recombinant mitochondrial gene expression. For example, the dual tetramer of domains D3 and D2 (denoted as D3x4_D2x4) protects mitochondrial complex I with higher efficiency than, for example the wild type 2.7 RNA.
[0078] Using computational methods, four thermodynamically conserved structural sub-domains within the 2.7 RNA were identified. All four domains showed substantial mitochondrial localization, and it was shown that the complete mitochondrial localization activity of the full-length 2.7 RNA could also be achieved by, for example, use of a single sub-domain termed domain 3. Furthermore, two of the four domains (for example, domains 1 and 4) exhibited highly similar structures on the antisense transcript and the antisense domains AS1 and AS4 exhibited substantial mitochondrial localization potential. A tetramer of, for example, sense domain 3 was found to have a twice higher mitochondrial localization activity and, in another example, a tetramer of domains 3 followed by a tetramer of domain 2 exhibited a three-fold higher activity compared with, for example the 2.7 RNA or domain 2.7 RNA-derived sequences were used to deliver recombinant nucleic acids into mitochondria in order to trigger mitochondria-specific phenotypes: Firstly, in one example, a coding RNA was furnished with mitochondria-specific start and stop codons, leading to mitochondria-specific recombinant gene expression; secondly, antisense RNAs targeting mitochondria-specific genes were used to trigger functional knockdown of mitochondria-specific gene expression. This technology therefore finds use in mitochondrial gene therapy or, for example, for mitochondrial delivery of non-nucleic acid compounds.
[0079] As an example of the use of the claimed invention, an exemplary method involves delivery of CMV 2.7 RNA-derived sequences with coding RNA into mitochondria, which in turn leads to recombinant mitochondrial gene expression. Delivery of CMV 2.7 RNA-derived sequences, for example, with antisense RNA into mitochondria triggers functional knockdown of mitochondrial gene expression. One example of such a delivery construct is a tetrameric repeat of the 2.7 RNA subdomain 3, which has been shown to exhibit enhanced mitochondrial localization potential. Exemplary arrangement of, for example two tetrameric repeats of 2.7 RNA subdomains 3 and 2 (D3x4_D2x4), which exhibit high mitochondrial targeting potential. Exemplary dual tetrameric of domains D3 and D2 (D3x4_D2x4) are shown to protect mitochondrial complex I with higher efficiency than the wildtype 2.7 RNA. Exemplary application of the outlined method is in genetic therapy, for example, to suppress mitochondrial malfunction or, in another example, to restore mitochondrial gene functions. Examples of application also include use in neurodegenerative or other mitochondria-associated diseases or for anti-aging.
[0080] Another example of the use of the claimed invention includes the use of the claimed nucleic acid delivery system together with CRISPR/Cas technology, that is using the claimed nucleic acid delivery system for delivery of the mRNA coding for the Cas9 endonuclease together with a single guide (sg)RNA, or for delivery of the respective genes coding for these components. The Cas9 enzyme together with the sgRNA can then form a ribonucleoprotein complex that can specifically cleave and functionally inactive defect mitochondrial genes or genomes.
[0081] A further application is to provide plasmid-based mitochondrial targeting vectors. A sequence of interest for the transcription of a coding or a non-coding RNA can be inserted either upstream or downstream to the mitochondrial targeting sequences. The chimeric RNAs can then be transcribed from the DNA templates either in vitro and then delivered into the target cells, or endogenously after transfection of target cells with the DNA vector. Variations of these vectors for the production of viral delivery particles, for example, but not limited to, lentiviral, adenoviral, adeno-associated virus, are envisioned as well.
[0082] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms comprising, including, containing, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
[0083] The invention has been described broadly and generically herein. Each of the narrower species and sub-generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
[0084] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0085] Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Experimental Section
[0086] Identification of Thermodynamically Conserved Structural Subdomains with the CMV 2.7 RNA
[0087] Using the software foldsplit, four thermodynamically conserved structural subdomains (named D1 to D4, respectively) within the non-coding 2.7 RNA of CMV were identified (
The CMV 2.7 RNA and Distinct Functional Subdomains thereof Localize to the Mitochondria of Human Cells
[0088] Mitochondrial localization, for example, (i) of the full-length 2.7 RNA, (ii) of each of the four single domains D1 to D4, and (iii) of single domain deletion constructs (
Distinct CMV 2.7 RNA Antisense Domains Localize to the Mitochondria of Human Cells
[0089] The antisense sequences of the constructs disclosed herein were considered for use as negative controls and therefore were also investigated in terms of their structures and thermodynamic conservation. Unexpectedly, the structure of the antisense 2.7 RNA was highly symmetric compared with the structure of the sense 2.7 RNA. A highly similar thermodynamic conservation was observed and it was possible to identify four conserved structural subdomains (D1_AS to D4_AS) in the corresponding position within the 2.7 RNA antisense sequence (
The CMV 2.7 RNA Co-Delivers Recombinant Coding RNA into the Mitochondria Leading to Mitochondrial Expression of a Recombinant Protein
[0090] A 2.7 RNA full-length RNA was fused to the 3 end of EGFP mRNA via a spacer sequence, which ensured that the active structure of the 2.7 RNA was not changing upon fusing it to the EGFP sequence (
The CMV 2.7 RNA Co-Delivers Antisense RNA into the Mitochondria Leading to Suppression of Mitochondrial Expression of a Recombinant Protein
[0091] Next, the 2.7 RNA was fused to computationally selected, unstructured antisense RNAs targeting the mitochondrial gene, for example, MT-ATP6 and MT-ATP8 which are both involved in mitochondrial ATP synthesis (
A Tetrameric Repeat of the 2.7 RNA Subdomain 3 Exhibits Enhanced Mitochondrial Localization Potential
[0092] It was aimed to improve the mitochondrial targeting potential of the 2.7 RNA, for example by using multiple repeats of the most active 2.7 RNA subdomains, in one example D3 and D2. Tetrameric repeats of domains D3 or D2 were constructed and investigated for mitochondrial targeting using rtRT-PCR (
The Arrangement of Two Tetrameric Repeats of 2.7 RNA subdomains 3 and 2 (D3x4_D2x4) Exhibits Highest Mitochondrial Targeting Potential
[0093] Next constructs comprising (i) four repeats of D3 followed by four repeats of D2 (D3x4_D2x4), or (ii) four repeats of D2 followed by four repeats of D3 (D2x4_D3x4), or (iii) alternating domains D3 and D2 [(D3_D2)x4] were tested. While D2x4_D3x4 and (D3_D2)x4 exhibited reduced mitochondrial targeting activities comparable with the full-length 2.7 RNA, construct D3x4_D2x4 was found to be about 3-fold more active (
The Dual Tetrameric of Domains D3 and D2 (D3x4_D2x4) Protects Mitochondrial Ccomplex I with Higher Efficiency than the Wwildtype 2.7 RNA
[0094] The 5 terminal part of the 2.7 RNA was reported earlier to protect the mitochondrial complex I from inhibitors such as rotenone. It was investigated as to whether domains D3 or D2 alone, or their multimeric arrangements, were able to protect complex I against rotenone when delivering either, for example, the in vitro synthesized RNAs or alternatively plasmids expressing the RNAs endogenously (
Strategies of Delivering Recombinant Nucleic Acids into Mitochondria using Mitochondrial Targeting Sequences
[0095] Recombinant RNA or DNA can be either covalently linked to mitochondrial targeting sequences or alternatively be non-covalently linked via complementary base pairing. The recombinant nucleic acid can be either single-stranded, linear double-stranded, circular single-stranded, or circular double-stranded. One or multiple mitochondrial targeting sequences can be used to form one mitochondrial targeting complex. (
Materials and Methods
Design of the Parental Construct
[0096] The purpose of designing the construct was to clone it into the pVAX1 (Invitrogen) and pEGFP-C1 (Addgene) vectors to study domain characteristics and transgene delivery respectively. The restriction sites were selected using the online algorithm NEBcutter v2.0. The construct was synthesized by Geneart (Life Technologies). The construct was subsequently cloned into the pVAX1 vector. The CMV promoter sequence was obtained from the pVAX1 plasmid vector. The CMV promoter was to facilitate expression of the RNA in animal cells. The T7 promoter was to facilitate in vitro transcription of the parental constructer whereas the SP6 promoter was inverted to facilitate in vitro transcription of the antisense RNA sequence. HindIII was used to linearize plasmid for T7 transcription and BspEI was used to linearize the plasmid for SP6 transcription. NheI, XbaI, and BcII sites were used for cloning, The SV40 poly A signal was added to facilitate Polyadenylation and nuclear export of mRNA. The spacer represents the vector sequence between the kanamycin promoter and the polyA signal and KanaP is the part of the promoter which is initially removed from the vector during cloning using BcII. DraIII was included to facilitate cloning into the pEGFP-C1 vector (see
Synthesis of the Single Domain Deletion Constructs (SDDC)
[0097] To study the effect of individual domains on 2.7 RNA function, constructs were generated having individual domains deleted. The strategy used to delete the domains was overlap extension PCR as indicated in
Overlap Eextension (OE) PCR Strategy for Synthesis of SDDC
[0098] Overlap extension polymerase chain reaction (OE PCR) was carried out in two steps. In the first step, the region upstream of the deletion domain (DD) was PCR amplified using a common forward primer which carries the NheI site and the OE reverse primer, which introduces the priming site for the region downstream of the DD. Subsequently, the domain downstream of the DD was PCR amplified using an OE forward primer, which introduces the priming site for the region upstream of the DD. and a common reverse primer, which carries the BamH1 site. Both PCR products were then gel-purified and mixed together in equimolar amounts and then re-amplified using PCR, in which the OE introduced priming sites acted as primers for their respective counterparts, thereby giving the full length construct with the desired deletion.
Synthesis of the Single Domain Constructs (SDC)
[0099] The Single domains were PCR amplified from the parental 2.7_pVAX1. The PCR conditions for each of the single domains were as follows: Single Domains 1(SD1_pVAX1): Using 2.7_pVAX1 as template PCR was carried out using D1F and D1R following which the PCR product was cloned using the BspEI and HindIII sites. The PCR conditions reaction mixture included 10 ng of template, 5 l of 10 Taq buffer, 4 mM of MgCl2,0.2 mM of each dNTP, 300 nM of each primer and 0.25 l of Taq Polymerase (ThermoScientific).The final volume was made up to 50 l with Ultrapure Nuclease free water (Invitrogen). The reaction conditions used were 94 C. for 5 minutes, 25 cycles of 94 C. for 30 seconds, 56 C. for 30 seconds, 72 C. for 30 seconds, 72 C. for 5 minutes. Single Domain 2 (SD2_pVAX1). Single Domain 3(SD3_pVAX1), and Single Domain 4 (SD4_pVAX1) constructs were generated the same way but using the specific PCR primer D2F and D2R, D3F and D3R or D4F and D4R instead (see
Strategy for Single Domain Amplification
[0100] The forward and the reverse primers were designed to introduce the BspEI and HindIII sites respectively. The PCR products were subsequently digested with BspEI and HindIII purified and cloned into the pVAX1 vector using the BspEI and HindIII sites.
Synthesis of the GFP Fusion Constructs
[0101] Design of the GFP Fusion constructs: All the GFP fusion constructs were designed using the pEGFP-C1 (Addgene) plasmid vector. The 2.7 RNA sequence was cloned downstream of the eGFP sequence in the plasmid using restriction sites BspEI and DraIII. Next the eGFP sequence was PCR amplified from the plasmid to introduce the restriction site at either end along with the spacer sequence. To enable mitochondria-specific gene expression, the start and stop codons of the eGFP message were modified with mitochondria specific start and stop codons. Since the analysis of GFP expression would be carried out using plasmid vectors primarily the structure of the CMV transcript was analysed for structural preservation using mfold. The PCR conditions are described below. 50 l PCR reaction was set up having 10 ng of pEGFP-C1 template, 5 mM of 10Xtaq buffer, 4 mM Mgcl2, 300 nm of each primer, 0.2 mM of each dNTP and 0.25 l of Taq Polymerase (ThermoScientific). The cycler was set at 94 C. for 5 minutes, 25 cycles of 94 C. for 30 s, 55 C. for 30 s, 72 C. for 1 minute, 72 C. for 10 minutes. The parental 2.7 sequence with the SV40 poly A was cut out from the 2.7_pVAX1 vector, gel purified and ligated downstream of the eGFP sequence using the BspEI and DraIII sites as indicated in
[0102] The cloning process described above creates the Genomic GFP+2.7. The 2nd control namely genomic GFP+Spacer+2.7 was created by amplifying the eGFP sequence from the original pEGFP-C1 vector by PCR using PCR primers with the reverse primer introducing the spacer sequence and the NheI site following which it was cloned back into the Genomic GFP+2.7 vector. To enable mitochondria specific expression, the start and stop codons of the eGFP sequence were modified using PCR primers with the forward primer introducing the mt start codon and the reverse primer introducing the spacer sequence and the mitochondria specific stop codon following which it was cloned back into the pEGFP-C1 vector carrying the 2.7 using NheI site to generate mtGFP+Spacer+2.7. In both these cases the GFP sequences were cloned into the vector using a single NheI restriction site and hence to prevent vector backbone re-ligation, it was dephosphorylated simultaneously with Alkaline phosphatase during digestion with NheI. As a negative control the mtGFP+spacer sequence with a portion of the CMV promoter was PCR amplified from the mtGFP+Spacer+2.7 plasmid using primers which carried NdeI and BamHI sites respectively. Simultaneously the pEGFP-C1 plasmid vector was digested between the NdeI site and BamHI site to remove the original GFP sequence and a part of the CMV promoter. The PCR product was then digested with NdeI and BamHI, purified and ligated back into the gel purified vector backbone which re-constitutes the CMV promoter and replaces the eGFP sequence with the mtGFP+spacer sequence.
Adding a SV40 Nuclear Localization Signal to the GFP Fusion Constructs
[0103] To facilitate imaging by confocal microscopy, a SV40 nuclear localization signal (NLS) was PCR amplified from the pEBFP_NUC (Addgene) and cloned downstream of the GFP sequence in all GFP expressing constructs, including the mitochondrial constructs. The NLS carries a mitochondria specific stop codon in frame and, as a result, only cytoplasmic GFP is targeted to the nucleus, whereas intra-mitochondrial GFP remains localized in the mitochondria. This is because translation in the mitochondria generates an incomplete NLS. The pEBFP-NUC plasmid carries 3 tandem repeats of the NLS sequence and hence the PCR primers were designed to flank the tandem repeats. PCR amplification and design strategy is explained in figure. Post-cloning, the constructs were screened using a single XhoI digestion. The PCR conditions were as follows. Using the pEBFP_NUC as a template PCR was carried out using the NLS_cloning Fw and NLS_cloning Rv following which the samples were PCR purified and cloned downstream of the GFP sequence between the Bsp1407I and the BspEI sites. The PCR conditions used were as follows: 10 ng of pEBFP-NUC template, 5 mM of Taq buffer, 4 mM Mgcl2, 0.2 mM of each dNTP, 300 nM of NLS_cloning Fw and NLS_cloning Rv respectively, 0.25 l of Taq Polymerase (ThermoScientific) and the volume was made up to 50 l with ultrapure Nuclease Free Water (Invitrogen). The cycling conditions used were 94 C. for 5 minutes, 25 cycles of 94 C. for 30 seconds, 52 C. for 30 seconds, 72 C. for 5 minutes.
[0104] The NLS sequence was PCR amplified from the pEBFP-NUC plasmid by PCR using forward and reverse primers which introduced BsrGI and BspEI sites, respectively (see
Synthesis of the Tandem Repeat Constructs
[0105] To study the interaction of the domains tandem repeats of two functional domains, in this example namely domains 2 and 3, were created. Four different arrangements were created as follows below.
Constructs having Four Copies of Domain 3(D3X4) and Domain 2(D2X4), Respectively
[0106] The strategy for generating the constructs were created as shown in
Domain 2 Tandem Repeats
Construction of Tandem Repeat Using a Multiple Ligation Process.
[0107] The individual copies were first synthesized is 4 sets using PCR primers (see
Construction Strategy for D3X4_D2X4
[0108] Similarly, the domain 2 tandem repeat (D2X4) was PCR amplified from the pVAX1 vector carrying D2X4 (see
Construction Strategy for D2X4_D3X4
[0109] Similarly, the domain 3 tandem repeat (D3X4) was PCR amplified from the pVAX1 vector carrying D3X4.The primer design strategy employed was the same as used for D3X4_D2X4. The PCR product was digested and re-ligated within the HindIII site of the de-phosphorylated pVAX1 vector carrying the D2X4 sequence.
Constructs having Alternate Repeats of Domain 3 and Domain 2 each (D3_D2)4
[0110] The alternative repeat construct was generated in four steps. Both D3X4 and D2x4 share the same set of restriction sites. Prior to the cloning the CMV and the T7 transcripts were validated using mfold and RNAfold. A detailed cloning scheme is described in
[0111] In the first step a single copy of domain 3 was cloned using the NheI and Ecorl site. In the 2nd step another copy of domain 3 was cloned between the KpnI and the AgeI sites. The product thus obtained is now used as PCR template using Domain 3 tandem Fw and Domain 2 tandem Rv both of which carry HindIII sites. The PCR product of the correct size is gel-purified and ligated back into the de-phosphorylated pVAX1 plasmid carrying the step 2 product. The clones were then screened by digestion and verified by sequencing (AITBiotech).
Design of Antisense RNA for Mitochondrial Targeting
Choice of Target and Selection of Candidates
[0112] The candidates for mitochondrial targeting used were Mt-ATP6 and Mt-ATP8, which are essentially subunits of the Complex V (ATPase). The antisense RNA targeting the two genes were designed using HUSAR foldanalyze at window sizes of 100, 200 and 300 and a shift of 1 nucleotide following which candidates with maximum number of unpaired bases at either the 5 or 3end were selected. These sequences were subsequently fused to the 2.7 RNA, either at the 5 end or the 3 end based on location of the open ends, and structural preservation was analysed using mfold.
Purification of the Target Sequences
[0113] Target sequences were obtained from isolated mitochondrial RNA using a procedure described in the figure below. The reaction conditions for reverse transcription were as follows: 500 ng of mtRNA was mixed with 1 l of 10 mM dNTP mix, 1 l of 2 uM gene specific reverse primer made up to a final volume of 14 l with RNase free water. The mixture was heated at 65c for 5 mins followed by snap chill on ice for 2 mins. This reaction mixture was then mixed with 4 l of 5 first strand buffer, 1 l of 100 mM DTT, 20U of RNaseOUT (Invitrogen), 0.5 l of SuperScriptlV, the final volume of the reaction being 20 l and incubated at 55 C. for 1 hour, followed by heat inactivation at 70 C. for 15 minutes.
Isolation of Target Sequences for Antisense Generation
[0114] Mitochondrial RNA was reverse transcribed with gene specific reverse primer sequences (ATP6Rv and ATP8Rv) to obtain first strand ATP6 and ATP8 cDNA pools. Subsequently these pools were used as templates for PCR to obtain double stranded DNA sequences representing the target elements (see
Cloning of Target Sequences to Generate the Antisense
Cloning of the ATP6 Antisense Sequence
[0115] Since the ATP6 antisense sequence had the maximum number of unpaired bases at the 5 end, it had to be fused to the 5 end of 2.7 sequence. To obtain the antisense sequence, the target sequence obtained from mitochondrial RNA pool was reversed and cloned into the 2.7_pVAX1 vector, downstream of the T7 promoter and upstream of the 2.7 sequence. The purified ATP6 target was PCR amplified using ATP6_Cloning_Fw and ATP6_Cloning_Rv.The cloning strategy is described in
Synthesis and Cloning of the ATP6 Antisense Sequence
[0116] The ATP6 target sequence was re-amplified by PCR to introduce restriction sites in an opposite orientation to that in 2.7_pVAX1 sequence. The resulting product was digested with NheI and BspeI and then ligated into the 2.7_pVAX1 vector backbone. The products were screened by digestion with NdeI and NheI. Subsequently a spacer sequence was introduced downstream of the this construct by nested PCR and then verified by sequencing (AITBiotech).
Cloning of the ATP8 Antisense Sequence
[0117] The ATP8 target sequence was cloned downstream of the 2.7 sequence, since the unpaired bases were primarily at the 3 end. The ATP8 target was amplified by nested PCR to introduce the desired restriction sites and the stabilizing spacer sequence, and cloned downstream of the 2.7 sequence (see
Cloning Strategy for Generating 2.7_ATP8 Fusion Construct
[0118] The Purified ATP8 target sequence was PCR amplified with the reverse primer introducing a SpeI site. Simultaneously, a fragment was amplified from 2.7 by PCR so that the resulting product carried a BamHI and HindIII site at the 5 end and at the 3 end, respectively. The 2.7 PCR product and the ATP8 PCR product were single digested with HindII and SpeI respectively, mixed in equimolar amounts and ligated at 22 C. for 3 hours using T4 DNA ligase (ThermoScientific). SpeI site can be ligated to HindIII site by a 2 base fill-in, which effectively destroys both restriction sites. Post-ligation, the product of the correct size was purified from the gel, the product this having the 2.7 fragment fused to the antisense ATP8 sequence. This ligation product was the PCR-amplified to introduce the BamHI and HindIII sites, respectively, and cloned back into the 2.7_pVAX1 vector backbone to generate the intact sequence. The clones were verified by BamHI and HindIII double digest, and then verified by sequencing (AITBiotech).
Synthesis of RNA by in Vitro Transcription
[0119] In vitro transcription was carried out using T7 (ThermoScientific) and SP6 RNA polymerase (ThermoScientific). SP6 Polymerase was used for synthesizing antisense RNAs and the 2.7_GFP RNAs. The rest of the RNAs were synthesized using T7 RNA polymerase. The last 6 bases of the T7 and the SP6 promoter were selected, respectively, as previously described, and ultimately become a part of the T7 and the SP6 transcripts, respectively.
Preparation of Templates for in Vitro Transcription
[0120] All plasmid vectors to be used for in vitro transcription were extracted overnight with Phenol:Chloroform:Isoamyl alcohol (25:24:1) and precipitated the next day using ethanol. The templates for in vitro transcription were prepared by PCR or by plasmid linearization. All restriction enzymes used for plasmid linearization generated 5 overhangs to prevent formation of runaway transcripts. In case of PCR synthesized templates, the forward primer introduced the sequence of the T7/SP6 promoter for in vitro transcription. Both PCR templates and linearized plasmids were purified by PCR purification kit (Qiagen).
In Vitro Transcription (IVT)
[0121] IVT was carried out using T7/SP6 RNA polymerase (ThermoScientific). lug of linearized plasmid/purified PCR template was incubated with 1 Transcription buffer, 10 mM NTP mix, 20U of RNaseOUT (Invitrogen) and 30U of SP6/T7 RNA polymerase in a final volume of 50 l at 37c for 2 hours. Post 2 hour incubation, 3U of DNase I was added to the reaction mixture and incubated for at least 30 minutes at 37 C. RNA was then purified by Phenol chloroform extraction.
Transfection
[0122] All transfections were carried out using Lipofectamine 2000 (Invitrogen) in Opti-MEM (GIBCO).
Transfection of HepG2 Cells for Analysis of RNA Uptake
[0123] HepG2 cells were grown in T75 flasks in DMEM with antibiotics and transfected at 90% confluency. Transfection was carried out in Opti-MEM (GIBCO). lug equivalent of 2.7 RNA and its derivatives was transfected as per manufacturer's protocol. Media was changed 6 hours after transfection. 24 hours after transfection Mitochondrial RNA was isolated for analysis by Real Time PCR.
Transfection of Hek293T Cells for Analysis of Mitochondrial RNA Knockdown
[0124] 10.sup.5 cells of 293T Hek293T were grown in 24-well plates in DMEM with antibiotics and transfected the next day. Transfection was carried out in Opti-MEM (GIBCO). 800 ng equivalent of antisense_2.7 fusion RNA was transfected as per manufacturer's protocol. Media was changed 6 hours after transfection. 24 hours after transfection, the total RNA was isolated and analysed by real time PCR.
Transfection of HepG2 Cells for FACS Analysis and Confocal Microscopy
[0125] For FACS analysis 30,000 HepG2 cells were grown in 24-well plates and transfected at 30% confluency. Transfection was carried out in Opti-MEM (GIBCO). 800 ng of the control pEGFP-c1 and 2.7_GFP fusion plasmids (+NLS) was transfected as per manufacturer's protocol. Media was changed 6 hours after transfection. 24 hours after transfection, the cells were trypsinised and analysed for GFP expression using flow cytometry. For confocal microscopy analysis 20,000 HepG2 cells were seeded in 1.5 uM Chamber Slides (iBIO). Area of a chamber in the slides has the same as that of wells in 48-well plates and thus, transfection was carried out accordingly. 400 ng of the control pEGFP_C1 and 2.7_GFP fusion plasmids (+NLS) were transfected as per manufacturer's protocol. 24 hours after transfection, the cells were stained with respective dyes and analysed using confocal microscopy.
Transfection of HEK293T for Cell Viability Analysis
[0126] 50000 HEK293T cells were seeded in 24-well plates. 800 ng equivalent of the 2.7 RNA was added to each well and total RNA/well was adjusted to 800 ng using RNA previously isolated from untreated HEK293T cells. Media was changed after 6 hours. 10.sup.5 Hek293T cells were seeded in 24-well plates and transfected with 1.5 g of 2.7 RNA_antisense fusion RNA. Since previously isolated RNA may contain target sequences hence the total RNA/well was adjusted to 1.5 g using feeder RNA (yeast tRNA) instead of isolated RNA. Media was subsequently changed 6 hours after transfection.
Transfection of Hek293T for CellTiter-Glo Assay
[0127] 25000 Hek293T cells were seeded in 96-well plates and transfected with 300 ng equivalent of the 2.7 RNA_antisense RNA. Amount of RNA per well was adjusted using feeder RNA. Media was changed 6 hours after transfection.
Isolation of RNA and Real Time PCR
Isolation of Mitochondrial RNA
[0128] Mitochondria were isolated from HepG2 cells using the Mitochondria Isolation Kit (Biochain) as per manufacturer's guidelines. The isolated mitochondria were re-suspended in 1 Mitochondria Isolation Buffer. To remove contaminating cytoplasmic RNA, the mitochondrial suspension was treated with RNaseA (ThermoScientific) as previously described. Post-incubation, RNase A was inactivated by addition of 2 volumes of Trizol Reagent, following which the RNA was extracted using Trizol Reagent (Invitrogen), as per manufacturer's guidelines.
Isolation of Total RNA
[0129] Hek293T cells seeded in 24-well plates were washed with 1 PBS. Subsequently, 200 l of Trizol Reagent was added. The mixture in the 24-well was resuspended until the solution loses viscosity. The components were then transferred to an Eppendorf tube and RNA was isolated as per manufacturer's guidelines.
DNase Treatment and cDNA Synthesis
[0130] 500 ng of isolated RNA (mitochondrial/total) was incubated with 1u DNase I (ThermoScientific) and 20U of RnaseOUT at 37 C. for 30 minutes. Post-incubation, ethylenediaaminetetraacetric acid (EDTA) was added to a final concentration of 3.75 mM and incubated at 75c for 12 minutes to inactivate DNase I. This reaction mixture was then reverse transcribed with 1 RT buffer, 5.5 mM MgCl2, 20U of RNaseOUT, 500 uM of each dNTP, 200 ng of Random Primers(Invitrogen), and 25U of multiscribe reverse transcriptase (ABI) at a final volume of 20 l at 37 C. for 2 hours, followed by heat inactivation at 85 C. for 15 minutes.
Real Time PCR
[0131] 1 l of cDNA was mixed with 5 l of 2 SYBR CFX master mix and 400 nm of each (forward and reverse) primer. Real Time PCR was carried out in ABI 7900HT Real Time PCR machine using the following Thermal cycling conditions: 50 C. for 2 minutes, 95 C. for 10 minutes, 40 cycles of 95 C. for 15 seconds and 60 C. for 60 seconds. Each sample was run in duplicates.
Relative Quantification
[0132] 12 s rRNA was used as an internal control for normalization. Relative RNA levels were determined using the CT method. Levels of cytoplasmic contaminant -Actin were determined by comparison with an untreated mitochondrial sample.
Absolute Quantification
[0133] In vitro transcribed RNA (to be transfected RNA) was serially diluted from 10.sup.10 to 10.sup.01 molecules, reverse transcribed and subjected to real-time PCR as described above. RNA standard curves were prepared by plotting Median CT values against the number of molecules per reaction. The copy number of each RNA (No. of molecules per micrograms (g) of isolated RNA) was determined by comparison with the respective standard curve using the SDS2.4 software.
Analysis of GFP Expression by Flow Cytometry
Sample Preparation
[0134] HepG2 cells seeded in 24-wells were trypsinized, following which the trypsin was inactivated by the addition of complete DMEM. Cells in DMEM were resuspended 8 to 10 times to free cell clumps, and subsequently pelleted in a centrifuge at 6000 g for 5 minutes. Cells were then washed with 1 PBS and re-suspended in complete DMEM for flow cytometry analysis.
Flow Cytometry Analysis
[0135] Flow cytometry analysis was carried out using a Beckmann Coulter CyAnADP flow cytometer. Cells were illuminated with a 488 nm laser, and gated using forward (FSC-A) and side scatter (SSC-A), along with doublet exclusion using FSC pulse width analysis. GFP expression was measured using a 510 nm to 540 nm bandpass filter. Up to 20,000 cells were measured on days 1, 3 and 5 post-transfection. Data was analysed using FlowJO 7.6.1.
Confocal Microscopy
[0136] Cells were transfected in chamber slides and analysed on 3.sup.rd day after transfection. Cells were stained with Hoechst 33342 (molecular probes) and/or Mitotracker Orange CMH2TMRos (Molecular Probes), as per manufacturer's guidelines. Cells were then counterstained with HCS CellMask Deep Red stain (Molecular Probes). Images were captured with Olympus FluoView FV1000 (Olympus, Japan) laser scanning confocal microscope, using a 60/1.00 water objective, with 405 nm solid state laser diode (Hoechst), 488 nm argon ion laser (GFP), 543 nm HeNe Green laser (Mitoctracker) and 633 nm HeNe Red (cell mask). Images were subsequently analysed using ImageJ V1.48.
Rotenone Induced Cell Death
[0137] 200 mM rotenone stock solutions were prepared in anhydrous DMSO (Sigma). Rotenone stock solution was diluted to a final concentration of 200 uM in compete DMEM and filtered using a 0.22 uM filter. 24 hours after transfection, rotenone_DMEM was administered to Hek293T cells and cell death was determined 24, 48 and 72 hours after transfection using an alamar blue assay. After cell death assessment, cells were washed with PBS and fresh drug was administered for analysis on the subsequent time point.
Alamar Blue Cell Viability Assay
[0138] Hek293T cells seeded in 24-well plates were subjected to alamar blue (Invitrogen) cell viability assay, as per manufacturer's guidelines. Fluorescence was measured at emission/excitation (530/590) using Biotek Synergy H1 Reader, with the sensitivity set to 60. The percentage (%) reduction in cell viability was determined by comparison with a cell-only control.
Measurement of ATP Levels
[0139] Hek293T cells were transfected in 96-well plates and ATP levels were determined 24 hours after transfection using a CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was measured using a TECAN infinite M200PRO plate reader. Absolute ATP levels were determined from ATP standard curve, prepared as per manufacturer's guidelines. Relative changes in ATP levels were determined by comparison with a cell-only control.
Statistical Analysis
[0140] Statistical analysis was carried out using GraphPad Prism Software 6.0. All numerical values presented as mean+SD (means plus standard deviation) of three independent experiments. Statistical significance was determined using Student's t-test and ANOVA.
Generation of Construct ATP6_(D3)4_(D2)4
[0141] A stabilizing spacer sequence was inserted in (D2)4 downstream of the final D2 repeat to yield the (D2)4_S construct. The (D2)4_S was PCR amplified with primers introducing HindIII sites at either end. Subsequently the PCR product was HindIII digested and cloned within the HindIII site to yield the ATP6_(D3)4_(D2)4 construct.
In Vitro Ttranscription (IVT) of Fluorescein-12 Uracil-Labelled RNA
[0142] Fluorescent RNA was synthesized by T7 RNA polymerase (Thermo Scientiflc) via in vitro transcription using fluorescein-12-UTP (Enzo). 1 g of linearized plasmid/purified PCR template was incubated with 5 l of 5 transcription buffer, 5 L of 10 mM NTP mix (10 mM GTP, 10 mM CTP, 10 mM ATP, 7.5 mM UTP, 2.5 mM fluorescein-12 UTP) 10 U of RNaseOUT (Invitrogen) and 20 U of T7 RNA polymerase in a final volume of 25 L at 37 C. for 3 h. 3 U of DNase I was the added to the reaction mixture and incubated for at least 30 min at 37 C. to remove DNA template. RNA was then purified using the PCR purification kit (Qiagen). Quality of RNA was analyzed on ethidium bromide-free 1.5% agarose gel. Gels were illuminated on UV trans-illuminator and captured using a Samsung galaxy S7 smartphone. Intensity of the bands was determined using ImageJ v1.48.
Confocal Microscopy
[0143] Cells were transfected in chamber slides and analyzed 24 h after transfection. Cells were stained with Hoechst 33342 (Molecular Probes), MitoTracker Orange CMH2TMRos (Molecular Probes) as per manufacturer's guidelines. Images were captured with Olympus FluoView FV1000 (Olympus, Japan) laser scanning confocal microscope using a 60/1.00 water objective , with 405 nm solid state laser diode (Hoechst) ,488 nm argon ion laser(GFP), 543 nm HeNe Green laser (Mitotracker) Images were subsequently analyzed using ImageJ V1.48. The extent of co-localization of GFP (green) within the mitochondrial (Red) fraction was determined using the plugin JACOP and the mander's overlap coefficient (MOC) was reported.
Tables
[0144]
TABLE-US-00002 TABLE 2 Overview of sequences presented in the attached sequence listing. AS stands for antisense; endo stands for endogenously transcribed RNA. These sequences were tested as plasmids. _core stands for core sequences, which are the minimum polynucleotide sequences (without spacers) that are operable. SEQ ID Restriction NO: Name Core Promoter sites Spacer Poly A Tested as in vitro transcribed RNA (no polyA) 1 Full length 2.7 Yes Yes Yes No No RNA (sense) 2 Full length 2.7 Yes Yes Yes No No RNA_AS (antisense) 3 Sense Domain 1: Yes Yes Yes No No D1 4 D2 Yes Yes Yes No No 5 D3 Yes Yes Yes No No 6 D4 Yes Yes Yes No No 7 Antisense Domain 1: Yes Yes Yes No No D1AS 8 D2AS Yes Yes Yes No No 9 D3AS Yes Yes Yes No No 10 D4AS Yes Yes Yes No No 11 Sense Domain 1 Deletion Yes Yes Yes No No Mutant: D1 12 D2 Yes Yes Yes No No 13 D3 Yes Yes Yes No No 14 D4 Yes Yes Yes No No 15 Multimer Sequence Yes Yes Yes Yes No D2 4 16 Multimer Sequence Yes Yes Yes Yes No D3 4 17 Multimer Sequence Yes Yes Yes Yes No D3 4_D2 4 18 Multimer Sequence Yes Yes Yes Yes No D2 4_D3 4 19 Multimer Sequence Yes Yes Yes Yes No (D3_D2) 4 20 gGFP_2.7 Yes Yes Yes Yes No 21 gGFP_s_r2.7 Yes Yes Yes Yes No 22 mtGFP_s_2.7 Yes Yes Yes Yes No 23 mtGFP_s Yes Yes Yes Yes No 24 asATP6_s6_2.7 Yes Yes Yes Yes No 25 2.7_s8_asATP8 Yes Yes Yes Yes No 26 asATP6_D3.sub.4_D2.sub.4 Yes Yes Yes Yes No Spacers (only) 27 S1a No No No Yes No 28 S1b No No No Yes No 29 S2a No No No Yes No 30 S2b No No No Yes No 31 S3a No No No Yes No 32 S3b No No No Yes No 33 S4a No No No Yes No 34 S4b No No No Yes No 35 S6a No No No Yes No 36 S6b No No No Yes No 37 S8a No No No Yes No 38 S8b No No No Yes No 39 Spacer FIG. 3a No No No Yes No Tested as in vitro transcribed RNA (no polyA) 40 Antisense Domain 1 Yes Yes Yes No No Deletion Mutant: D1AS 41 D2AS Yes Yes Yes No No 42 D3AS Yes Yes Yes No No 43 D4AS Yes Yes Yes No No Tested as plasmid DNA (endogenous transcript, all features) 44 gGFP_2.7_endo Yes Yes Yes Yes Yes 45 gGFP_s_2.7_endo Yes Yes Yes Yes Yes 46 mtGFP_s_2.7_endo Yes Yes Yes Yes Yes 47 gGFP_NLS_s_2.7_endo Yes Yes Yes Yes Yes 48 mtGFP_s_endo Yes Yes Yes Yes Yes 49 Full length 2.7 Yes Yes Yes Yes Yes RNA_endo (sense) 50 2.7 RNA domain Yes Yes Yes Yes Yes 2_endo (sense) 51 2.7 RNA domain Yes Yes Yes Yes Yes 3_endo (sense) 52 Multimer sequence Yes Yes Yes Yes Yes D2 4_endo 53 Multimer sequence Yes Yes Yes Yes Yes D3 4_endo 54 Multimer sequence Yes Yes Yes Yes Yes D3 4_D2 4_endo 55 2.7 core Yes No No No No 56 D1_core Yes No No No No 57 D2_core Yes No No No No 58 D3_core Yes No No No No 59 D4_core Yes No No No No 60 D1 _core Yes No No No No 61 D2_core Yes No No No No 62 D3_core Yes No No No No 63 D4_core Yes No No No No 64 2.7 RNA_AS_core Yes No No No No 65 Domain 1 antisense: Yes No No No No D1AS_core 66 D2AS_core Yes No No No No 67 D3AS_core Yes No No No No 68 D4AS_core Yes No No No No 69 D1AS_core Yes No No No No 70 D2AS_core Yes No No No No 71 D3AS_core Yes No No No No 72 D4AS_core Yes No No No No 73 Multimer sequence Yes No No No No D2 4_core 74 Multimer sequence Yes No No No No D3 4_core 75 Multimer sequence Yes No No No No D3 4_D2 4_core 76 Multimer sequence Yes No No No No D2 4_D3 4_core 77 Multimer sequence Yes No No No No (D3_D2) 4_core Fusions of the sense 2.7 RNA to different payloads but excluding promoter, spacer, restriction site, and polyA sequences 78 gGFP_2.7 (core) Yes No No No No 79 gGFP_s_2.7 (core) Yes No No No No 80 mtGFP_s_2.7 (core) Yes No No No No 81 mtGFP_s (core) Yes No No No No 82 asATP6_s6_2.7 (core) Yes No No No No 83 2.7 _s8_asATP8 (core) Yes No No No No 84 ATP6_(D3).sub.4_(D2).sub.4 Yes No No No No (core)
TABLE-US-00003 TABLE3 Sequences.Thefollowingsequences1to26and44to47weretestedasinvitro transcribedRNAusingasDNAtemplateeitherlinearizedDNA(RNAendingwith cleavagesite)orPCTproducts(RNAendingwiththeendofthePCRtemplate). Aspromoters,eithertheT7RNA(RNAstartswithGGCGCU)ortheSP6(RNAstarts withGGAGUC)promoterwasused.Afterthe6transcribedpromoternucleotides, thereiseitherarestrictionsiteornot. SEQ ID Name NO: (type) Sequence 1 Fulllength GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC B2.7RNA GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG (sense) GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAG GUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCC CCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUC CGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCG CAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAG ACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAA GCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAAC GAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGA AACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUC CUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGA CGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGA GAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGU CGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCC GGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAA GAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACC CGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUU UCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGA CACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAA CAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAG UAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCG CACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGA UGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUAC UACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGU UUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCA AUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGU AGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUC AAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUU AGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACA GAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACA CUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGAC UUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAA GACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACA AUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGG AUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAU CUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUU UCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCG GUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUU UUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAG AGUAGUAGACACAAUAAAUGAGAAGUUUGCAUGCAAGCU 2 Fulllength GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUAC B2.7RNA UCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAAA (antisense) AAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUGC GACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUAG GGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAGC UGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUUG UGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGAG AAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUUU UGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGCG AUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACAG GAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCGA GUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAGU ACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGUG UACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAUC UACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAAG AUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUAU CCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUCU UUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCCA UGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGCG AAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGA GUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGA UGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAG AGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUU UUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGA CUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGU AUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAU UCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAG CGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUCU CUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGA AUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAU CUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCG UUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUU CUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGU GAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGU UUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGU UGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUGG UUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAUG UGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCAU CUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAG GCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGG UGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUA AAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGAA UCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACCC AAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUG CGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAA GGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUAAUAAAACAGAAG CCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAACG GAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCG GUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUG CAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGG GAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGC GGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGA CCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCU CCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUC CCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCC GGGGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGAUGUGC UAGCUCCGG 3 Sense GGCGCUUCCGGACAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGU domain1: CGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCG D1 CCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGU CGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCG AAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAU GUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGC AGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGAC UACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCU GCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGAAGCU 4 Sense GGCGCUUCCGGAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUC domain2: GGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA D2 AACAAGAGGGUAAAAAGAAAAAAAGCU 5 Sense GGCGCUUCCGGAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACA domain3: ACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAG D3 GGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGA GGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGG UCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACAAGCU 6 Sense GGCGCUUCCGGACGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCC domain4: ACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAG D4 UAUCUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAA GAAACCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUAC GAUAAACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAG ACCACCUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGC ACCAUGAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUU UAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAG UCAUCCAUUUUUAUCCUCGCAAGCU 7 Antisense GGAGUCAAGCUUCAGAAGCCGACCGGCCGCCGACCCGUUCCCCAG domain1: GACCAGCCUACGAGGAACGGAUAACGCGGUGGCGACGGCAGCGGU D1AS GGUGGCGCUGGGGGUGGCGGUAGUGGUGCUGCUGAUGGUAGUCG GGACGGAGGAGAGACGAUGCAUACAUACACGCGUGCAUGCUGCAU GGGUGGAUGGUACGGCCGGGAGACGCGGAAGAGAAACUCACAUAA AAAGGUGAUAAAAAGAGCGGUUGAAAAAAGAAAACGAGAUUCGA CCAGACAGAAGAGAAGGACCGGGGCUUGGCGACCCUUCCACGACU GCCGUUGUCAUCUCGGCUCCUCCAUCUUCUCCCGGCCACGGGCGGC UAAGUCACCGCCGUUCUCCCCAUCCGUCCGAGCGCCGACCGACCAG CCGGCCGAUUCGCCCGCCGGGGCUUCUGUCCGG 8 Antisense GGAGUCAAGCUUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCG domain2: AUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGG D2AS AAAGGAGAAGAUAAAAAAUAAAAUCCGG 9 Antisense GGAGUCAAGCUUGUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCG domain3: ACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGGACAC D3AS GGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCCAUG AGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGCGGA UUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUGUU GACGAUGAGGAUAAAUAAAAAUGACCUCCGG 10 Antisense GGAGUCAAGCUUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCC domain4: AGGGAGUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCC D4AS GAUGAUGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGA CGGAGAGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUU UUCUUUUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAA AUCGACUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAU CAUGUAUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGA GCAAUUCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCG AUCAGCGGCAUGCCGACGCCGUCCGG 11 Sense GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC domain1 GUUCUCUUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCU deletion UAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCA mutant: GAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUG D1 GGUACCUCAGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAU UCCCAACAAGAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCA AGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUG UCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUG AAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAU CCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCA GAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACA ACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACA ACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGU CCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAA ACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAACCACAAACGACU ACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUA GUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUU ACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAA ACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAU CGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGC UCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUG AUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAU UUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAA AAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCG UCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCG GAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUG GACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCU CAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAA UACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAA AAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUA GAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCU CGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAU UCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGA GACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACAC CAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUA GGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGA CACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAU CCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAU CUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGA ACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAA CAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCC CAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUU GCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAU UCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCC UUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGUUUGCAUGCAAGCU 12 Sense GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC domain2 GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG deletion GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG mutant: GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA D2 AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUAGCUACAGACAU UUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGAC GAUUCCCAACAAGAGAAAACAGAACAAAAACAAGGUCAUUUUUAU UUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCA CCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGC CUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAG AUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCA CAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAA CCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCA ACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAA ACAACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCA CGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGA AAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAACCACAAAC GACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGA UUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAU UCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAG AGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCG CUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGA AUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAU ACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAG UCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAA AAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCU CUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAU CAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACU CCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACC UAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUU ACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGA UAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUC ACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAA CGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAA AAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGU GAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAA ACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUU CUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAU AUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGA UUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUU UGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGAC ACAAUAAAUGAGAAGUUUGCAUGCAAGCU 13 Sense GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC domain3 GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG deletion GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG mutant: GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA D3 AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAA GAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACA ACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACA ACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGU CCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAA ACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAACCACAAACGACU ACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUA GUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUU ACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAA ACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAU CGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGC UCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUG AUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAU UUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAA AAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCG UCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCG GAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUG GACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCU CAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAA UACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAA AAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUA GAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCU CGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAU UCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGA GACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACAC CAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUA GGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGA CACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAU CCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAU CUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGA ACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAA CAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCC CAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUU GCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAU UCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCC UUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGUUUGCAUGCAAGCU 14 Sense GGCGCUUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUGCCCCGGC domain4 GUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCG deletion GCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUG mutant: GCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGA D4 AGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUC GUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGU UUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGC ACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUC AGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCG CCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGU CGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAG GUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCC CCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUC CGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCG CAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAG ACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAA GCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAAC GAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGA AACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUC CUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGA CGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGA GAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUACUUCU UCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAAC AUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAA AGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGA UAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUC UUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAG AUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACA CCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUAC UUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCG GAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUG UCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGC AACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAA AAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUC GUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAA AAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUU UUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGU AUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACG GAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUG UUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAG ACACAAUAAAUGAGAAGUUUGCAUGCAAGCU 15 Multimer GGCGCUUCCGGAAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUC sequence CUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCG D2x4 CAGAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCG AUCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGG GUAAAAAGAAAAAGAUCGUAUCCGGUACCUGUGGUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUA CCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA CCACACCUCCACCGGUGGGCCGUUUUAUUUUUUAUCUUCUCCUUU CCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUC GCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACGGCCCAAGCU 16 Multimer GGCGCUUCCGGAAGAGCUAGCCCGGCGGUCAUUUUUAUUUAUCCU sequence CAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAA D3x4 UGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG GAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUAUCCUCAU CGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGU CAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAU CCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAU CCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGC GUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGAUCGAAUA AAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAAC AACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAA GGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAG CAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUAAU ACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGU UCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCG CGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGA UUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAA ACAAUCAUAGGAAAUGAACCCCCCGGAAGCU 17 Multimer GGCGCUUCCGGAAGAGCUAGCCCGGCGGUCAUUUUUAUUUAUCCU sequence CAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAA D3x4_D2x4 UGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG GAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUAUCCUCAU CGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGU CAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAU CCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAU CCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGC GUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGAUCGAAUA AAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAAC AACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAA GGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAG CAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUAAU ACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGU UCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCG CGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGA UUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAA ACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCGGAAGAGCUA GCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAU UUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUUUAUCUUC UCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCA CGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGU AUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAU CUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUG AUAAACAAGAGGGUAAAAAGAAAAACCACACCUCCACCGGUGGGC CGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAU UUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACCUAA AUGUCUAG 18 Multimer GGCGCUUCCGGAAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUC sequence CUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCG D2x4_D3x4 CAGAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCG AUCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGG GUAAAAAGAAAAAGAUCGUAUCCGGUACCUGUGGUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUA CCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA CCACACCUCCACCGGUGGGCCGUUUUAUUUUUUAUCUUCUCCUUU CCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUC GCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACGGCCCAAGCUUC CGGCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGA CAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCC UGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCG AUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUU CCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACA AUCAUAGGAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUC GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAAC AACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCC CCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCU CCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUU UUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAAC ACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGAC GCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAG GUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCC UGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCCCACAUUUUACCGGUAAUACCGGGGGGUCAUUUUUAUUU AUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACC AAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCU GUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAU GAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACA UCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACC CCCCGGAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAG 19 Multimer GGCGCUUCCGGAAGAGCUAGCCCGGCGGUCAUUUUUAUUUAUCCU sequence CAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAA (D3_D2)x4 UGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG GAAGCGCCGAAUUCCGAUCUUUUAUUUUUUAUCUUCUCCUUUCCU UAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCA GAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGUAUCCGGUAC CUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACC GACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCCCACAUUUUACCGGUGGGCCGUUUUAU UUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAACGGCCCAAGCUUUCCGGAAGAGCUAGCCCGGCGGUCAUUUU UAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACA CCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACG CGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGG UAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCU GCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAU GAACCGCCGGGAAGCGCCGAAUUCCGAUCUUUUAUUUUUUAUCUU CUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACC ACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCG UAUCCGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAAC AACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCG CAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUG GGCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAU CAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACC UAAAUGUCUAG 20 gGFP_2.7 GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUGGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAUGAGCUAGC UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCU UCUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCU UUUUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCC GUACCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGU CUCUCCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCC CCAGCGCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCG UAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUU UUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCG GAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAA ACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCA GCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAA GAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCG UCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCA AUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCC UCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCC CGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCG UCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAA AAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACAACAACCGCA UCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUG AGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUU UUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUA GAUAAAUAUAAAAAAAAAUAGAAACCACAAACGACUACUAGUACU CCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCA UAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCU GCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAU CCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGC CCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAA AAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGA AAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCAC UACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAA GAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUC UGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUC UUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAG GAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGC CUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUU AAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAAAAAAACAAC UUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUAGAGUGUAG GCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAA UCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAUUCACAUCA ACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGAGACAGCCC UUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACACCAAAGAA GAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUAGGAAUCA AGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGACACCGCG CCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAUCCAUCGU GAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAUCUUGGAC CACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGAACUUUGA GAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAACAACCUC UGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCCCAAACCU CGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCCU UAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAUUCCUUCU GCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACCC CCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAAUAAAUGA GAAGUAAGCU 21 gGFP_s_2.7 GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUGGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAUGACACCAC CCCGGAGAACAGCUCCUCGCUAGCUCCCCAGAUCGCUGCUGCCCCG GCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGU CGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCG UGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUG GAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUC UCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGA GUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAU GCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCA UCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGU CGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGG GUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUA CCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA AGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAA UUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAA GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAAC AACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCC CCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCU CCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGU AUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAA GACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCA AGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAA CGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAG AAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCU CCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAG ACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAG AGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCG UCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCG CCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAA AGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAAC CCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAU UUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGG ACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUA ACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCA GUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUC GCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGG AUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUA CUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGG UUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCC AAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAG UAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAU CAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUU UAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAAC AGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACAC ACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGA CUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAA AGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGAC AAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAG GAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUA UCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUU UUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUC GGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUU UUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUAAGCU 22 mtGFP_s_2.7 GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUAGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAAAGACACCA CCCCGGAGAACAGCUCCUCGCUAGCUCCCCAGAUCGCUGCUGCCCC GGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGG UCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCC GUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGU GGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAU CUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUG AGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCA UGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACC AUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCG UCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACG GGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUU UUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCU ACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAA AAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGA AUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACA AGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAA CAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGC CCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCC CGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAU CAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUG UAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCA AGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACC AAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAA ACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUA GAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGC UCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAA GACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUA GAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGC GUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGC GCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAA AAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAA CCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGA UUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCG GACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAU AACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGC AGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCU CGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAG GAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUU ACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAG GUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGC CAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUA GUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCA UCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUU UUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAA CAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACA CACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUG ACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAA AAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGA CAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUA GGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUU AUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACAC AGAGUAGUAGACACAAUAAAUGAGAAGUAAGCU 23 mtGFP_s GGAGUCUCAGAUCCGCUAGCGCUACCGGUCGCCACCAUAGUGAGC AAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAG CUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAG GGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUC UGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCA CCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAU GAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGU CCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGAC CCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAU CGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGG GCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAU GGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCG CCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCA GCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAAC CACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAG AAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGG AUCACUCUCGGCAUGGACGAGCUGUACAAGUCCGGAAGACACCAC CCCGGAGAACAGCUCCUC 24 asATP6_s6_ GGAGUCUCCGGAAUAAGCGCCAGUAGAAUUAGAAUUGUGAAGAU 2.7 GAUAAGUGUAGAGGGAAGGUUAAUGGUUGAUAUUGCUAGGGUGG CGCUUCCAAUUAGGUGCGUGAGUAGGUGGCCUGCAGUAAUGUUAA AGCAAGGGUUAUUCCGAAUUGGGCUAGCUCCCCAGAUCGCUGCUG CCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGG UCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCC GCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAG UCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUC GAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUA UGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUG CAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGA CUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGG GAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUU AUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCU CUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAA GAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUC GAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAA AAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACC GACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCG GUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCC GCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACA ACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUC AAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAA AUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUA UGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGA AAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUG UAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCG GCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCG GCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAA AAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAG AACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAA GAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGG CGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCA AUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUU GCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUC CUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAA AGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUU UUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUU AGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCA GCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAA UAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAG CAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGC UUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAA AACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAA CACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGU GACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA AAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAG UUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGC UCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCC UUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACA CAGAGUAGUAGACACAAUAAAUGAGAAGUCCAAUUCGGAAUAACC CAAGCU 25 2.7_s8_as GGCGCUUCCGGAAUAGGUUGGAUUGGGGGCUAGCUCCCCAGAUCG ATP8 CUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCC GGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGAC UUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAA CGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGU CUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACC UUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCA CCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCG UCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCAC CACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGU CCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUU UUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAU UUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGA UAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACA GAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACA ACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAG GGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGA GGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGG UCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAU CUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAA UCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUA UUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAU AAAAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUA GAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCG AAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGG UCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUC CCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUC GGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCU UUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACC AACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAA CACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCU UCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGA UUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAA UCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCA UUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUU GAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGU AUCACCAUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAG UAUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGA AACAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUC UGCAUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAA AAACUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUA GUUUGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCC UUACGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUG CACUGAAAACACACUCUCCUGUCACGACACCGCGCCACACCAGAG GCGUACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCG CAGAACCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCG AUUCUUGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUU GAAACCUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAA UGCGCUAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCC UAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAG AAGCACAAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUU AUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCC UGUAGCAACACAGAGUAGUAGACACAAUAAAUGAGAAGUAAGCU UCCCCAAACCAACCUCUACCGGAAGCGCCUUUUUUUCGUUCAUUU UGGUUCUCAGGGUUUGUUAUAAUUUUUUAUUUUUAUGGGCUUUG GUGAGGGAGGUAGGUGGUAGUUUGUGUUUAAUAUUUUUAGUUGG GUGAUGA 26 ATP6_D3.sub.4_ GGAGUCUCCGGAAUAAGCGCCAGUAGAAUUAGAAUUGUGAAGAU D2.sub.4 GAUAAGUGUAGAGGGAAGGUUAAUGGUUGAUAUUGCUAGGGUGG CGCUUCCAAUUAGGUGCGUGAGUAGGUGGCCUGCAGUAAUGUUAA AGCAAGGGUUAUUCCGAAUUGGGCUAGCCCGGCGGUCAUUUUUAU UUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCA CCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGC CUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAG AUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCA CAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAA CCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCA AGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUG UCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUG AAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAU CCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCG AUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUC GUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUC AAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUC CUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUC CCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCG UCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUUA CCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGC AAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGG CGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUC CGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCG GAAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUC GGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA AACAAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAU UUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAGAUCGUAUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUC CUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACG AAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACCACACCUC CACCGGUGGGCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCU CGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAU AAACAAGAGGGUAAAAAGAAAAACGGCCCCCAUGAAUAAGGCCCA AGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAUACUAAGGGA GUCUUGC 27 S1a CCGGC 28 S1b GCCGG 29 S2a CGAUC 30 S2b GAUCG 31 S3a UGUGG 32 S3b CCACA 33 S4a CCGGGG 34 S4b CCCCGG 35 S6a AAGCAAGGGUUAUUCCGAAUUGG 36 S6b CCAAUUCGGAAUAACCC 37 S8a GGUUGGAUUGGGG 38 S8b CCCCAAACCAACCUCUACCGGAAGCGCCUUUU 39 Spacer CACCACCCCGGAGAACAGCTCCTC FIG.3a ThesamespacerwasfoundtostabilizealltheGFPfusionconstructs 40 Antisense GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUAC domain1 UCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAAA deletion AAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUGC mutant: GACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUAG D1AS GGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAGC UGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUUG UGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGAG AAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUUU UGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGCG AUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACAG GAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCGA GUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAGU ACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGUG UACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAUC UACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAAG AUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUAU CCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUCU UUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCCA UGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGCG AAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGA GUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGA UGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAG AGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUU UUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGA CUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGU AUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAU UCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAG CGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUCU CUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGA AUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAU CUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCG UUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUU CUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGU GAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGU UUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGU UGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUGG UUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAUG UGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCAU CUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAG GCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGG UGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUA AAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGAA UCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACCC AAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUG CGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAA GGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUAAUAAAAGAGAAC GCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG 41 Antisense GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUAC domain2 UCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAAA deletion AAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUGC mutant: GACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUAG D2AS GGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAGC UGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUUG UGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGAG AAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUUU UGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGCG AUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACAG GAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCGA GUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAGU ACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGUG UACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAUC UACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAAG AUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUAU CCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUCU UUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCCA UGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGCG AAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGA GUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGA UGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAG AGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUU UUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGA CUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGU AUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAU UCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAG CGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUCU CUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGA AUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAU CUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCG UUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUU CUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGU GAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGU UUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGU UGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUGG UUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAUG UGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCAU CUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAG GCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGG UGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUA AAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGAA UCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACCC AAAUGUCUGUAGCUAAAAAUAAUAAAACAGAAGCCGACCGGCCGC CGACCCGUUCCCCAGGACCAGCCUACGAGGAACGGAUAACGCGGU GGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCGGUAGUGGUGCU GCUGAUGGUAGUCGGGACGGAGGAGAGACGAUGCAUACAUACACG CGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGGGAGACGCGGAAG AGAAACUCACAUAAAAAGGUGAUAAAAAGAGCGGUUGAAAAAAG AAAACGAGAUUCGACCAGACAGAAGAGAAGGACCGGGGCUUGGCG ACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCCAUCUUCUCC CGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAUCCGUCCGAG CGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGCUUCUGGAG AACGCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG 42 Antisense GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUAC domain3 UCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAAA deletion AAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUGC mutant: GACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUAG D3AS GGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAGC UGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUUG UGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGAG AAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUUU UGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGCG AUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACAG GAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCGA GUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAGU ACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGUG UACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAUC UACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAAG AUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUAU CCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUCU UUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCCA UGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGCG AAGAAGUGCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGA GUCGACUACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGA UGAUGUUGUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAG AGGAGCGUGUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUU UUUUCAAGAAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGA CUGAUCUCGGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGU AUUGUUUUCUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAU UCCUCGCCCGGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAG CGGCAUGCCGACGCCGACCCGGGGAUCUUGGAUUCACCGUUUUCU CUCUUCUCUCUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGA AUCAUCGUCGUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAU CUUAUCUAGGAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCG UUUGUGGUUUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUU CUGUUUUUCGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGU GAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGU UUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGU UGGUGUUGCUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUUU GUUUUUGUUCUGUUUUCUCUUGUUGGGAAUCGUCGACUUUGAAU UCUUCGAGUUAUCGGAAAGCUGAGGUACCCAAAUGUCUGUAGCUU UUUUCUUUUUACCCUCUUGUUUAUCAUCUGCGAUUCGUGGUAGGU AGGAGAGGGAAAUGAUAAUCCGAGAUUAAGGAAAGGAGAAGAUA AAAAAUAAAAAAAAAUAAUAAAACAGAAGCCGACCGGCCGCCGAC CCGUUCCCCAGGACCAGCCUACGAGGAACGGAUAACGCGGUGGCG ACGGCAGCGGUGGUGGCGCUGGGGGUGGCGGUAGUGGUGCUGCUG AUGGUAGUCGGGACGGAGGAGAGACGAUGCAUACAUACACGCGUG CAUGCUGCAUGGGUGGAUGGUACGGCCGGGAGACGCGGAAGAGAA ACUCACAUAAAAAGGUGAUAAAAAGAGCGGUUGAAAAAAGAAAA CGAGAUUCGACCAGACAGAAGAGAAGGACCGGGGCUUGGCGACCC UUCCACGACUGCCGUUGUCAUCUCGGCUCCUCCAUCUUCUCCCGGC CACGGGCGGCUAAGUCACCGCCGUUCUCCCCAUCCGUCCGAGCGCC GACCGACCAGCCGGCCGAUUCGCCCGCCGGGGCUUCUGGAGAACG CCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG 43 Antisense GGAGUCAAGCUUGCAUGCAAACUUCUCAUUUAUUGUGUCUACUAC domain4 UCUGUGUUGCUACAGGGAGUGAAGGGGGUGAAGGCAAACAAAAA deletion AAAAAGGAACAAAAUAAUAGAUUAGCAGAAGGAAUAAUCCGUGC mutant: GACCGAGCUUGUGCUUCUUUUCUUAUAAGGAGGCAAAUAUACUAG D4AS GGAAAACUUAAGAAUAGGAAGAAACCGAGGUUUGGGAGAAAAGC UGAGAUAAAAUAGCGCAUUUUCCAUACAGAGGUUGUUGUUUUUG UGGAUCCUAAGAGGUUUCAAGUGCGAAUCUCAAAGUUCUCACGAG AAUAUUGUCUUCAAGAAUCGACAACUGUGGUCCAAGAUUUUUUUU UGGUCUUUUUAGGUUCUGCGAGGGACAUCACGAUGGAUCGUUGCG AUGAAGUCACGCGUACGCCUCUGGUGUGGCGCGGUGUCGUGACAG GAGAGUGUGUUUUCAGUGCAGAGCUGUCUUGAUUCCUAUAUCCGA GUAUCUGUUUUCUCGUAAGGACGGUAAUCUUCUUUGGUGUAAGU ACAUCUAAAAGCUGCAAACUAUAUUUUAAGGGCUGUCUCUAGGUG UACUUUGAUGCUGGAGUUUUUCGCUGUGUUGAUGUGAAUAAAUC UACUACUACUAUUAUAUGCAGAAAGAGUGAUUAUGCCGAGACAAG AUUGCAUUGGCUGAACUGUUUCAAAAACGCCUACACUCUACUUAU CCGUAAACCUAAGGUAAUACUAUGUGUAAGUUGUUUUUUUUUCU UUUUGUAGUAAAAUGGUGAUACGUGCAAUUAAAACUGUAUUCCA UGUUUCCAUCCUUUCAUUUCAACUUUAAAGGCGGCUUUGAGAGCG AAGAAGUACCCGGGGAUCUUGGAUUCACCGUUUUCUCUCUUCUCU CUCUACAUACAGACCGGGUGGCAGGAGCGGUAAGGAAUCAUCGUC GUCUUUCAUUCUUCGAUGAUUAUGGUAAUACUAAAUCUUAUCUAG GAGCAUAUACAUCUAAGAUUGGAGUACUAGUAGUCGUUUGUGGU UUCUAUUUUUUUUUAUAUUUAUCUAUGACAGUUUUUCUGUUUUU CGUUUUGAUAAUAAUAUAAUAAAAACUCAUGGACGUGAAAUCUG GCUUGGUUGUGGUGAUUUCAUUCUCAUUAUUGUUGUUUUCUUUCC GUCUUGCGGAUGAAGAUGUUGCGAUGCGGUUGUUGUUGGUGUUG CUAUACACCGAGAGAGAUGAUCUUUUUGUUCUUCUGGUUCAUUUC CUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAUGUGCAGGGC AUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCAUCUACCUAU ACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAGGCGCGUCG AGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGGUGGUGUUU CGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUAAAUAAAAA UGACCUUGUUUUUGUUCUGUUUUCUCUUGUUGGGAAUCGUCGACU UUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACCCAAAUGUCUG UAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCGAUUCGUG GUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGGAAAGGAG AAGAUAAAAAAUAAAAAAAAAUAAUAAAACAGAAGCCGACCGGCC GCCGACCCGUUCCCCAGGACCAGCCUACGAGGAACGGAUAACGCG GUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCGGUAGUGGUG CUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUGCAUACAUACA CGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGGGAGACGCGGA AGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGCGGUUGAAAAA AGAAAACGAGAUUCGACCAGACAGAAGAGAAGGACCGGGGCUUGG CGACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCCAUCUUCU CCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAUCCGUCCG AGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGCUUCUGG AGAACGCCGGGGCAGCAGCGAUCUGGGGAUGUGCUAGCUCCGG
[0145] The following sequences were transfected as plasmid DNA using a CMV promoter and the SV40 polyA site. Hence the endogenously transcribed RNAs all start with UCAGAUCC which are the transcribed nucleotides of the CMV promoter then followed by a cleavage site, and they all end with UUUUUUUCACUGC(A).sub.n. The bold Cs indicate the two polyA cleavage sites which are then being followed by a polyA stretch (A).sub.n. so the correct end of the sequence might be either ..UUUUUUUCACUGC(A).sub.n or . . . U(A).sub.n.
TABLE-US-00004 SEQ ID NO: Name Sequence 44 gGFP_2.7_ UCAGAUCGCUAGCGCUACCGGUCGCCACCAUGGUGAGCAAGGGCGA endo GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAAGAGCUAGCUCCCCAGAUCGCUGCUG CCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGU CGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCG CCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGU CGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGA AUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUG UGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAG CAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUAC CAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCG UCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGG GUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUAC CUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAA GCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAU UCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAG GUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAA CGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCC UCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGU AUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAU GCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGG AAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGC AACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGA AAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAG AUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAA ACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAACCAC AAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAU AAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGACGAU GAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAG AGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCC GCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGA AUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUA CAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGU CGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGAAAAA AGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCU CCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAU CGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCU GGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCU CAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAAU ACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAGAAAAA AAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUAAGUAG AGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCUC GGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAUU CACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGAGA CAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUACACCA AAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAUAUAGG AAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCACGACAC CGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGAUCCAU CGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAAUCUUG GACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAGAACUU UGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACAACAACC UCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUCCCAAAC CUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCC UUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUAUUCCUUC UGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACC CCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAAUAAAUGA GAAGUAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAAACU UGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAGCAUCA CAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A).sub.n 45 gGFP_s_2.7_ UCAGAUCGCUAGCGCUACCGGUCGCCACCAUGGUGAGCAAGGGCGA endo GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAUGACACCACCCCGGAGAACAGCUCCU CGCUAGCUCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCC CGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGG GGAGAACGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGA GGAGCCGAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCG GUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCG CUCUUUUUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCG GCCGUACCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUC GUCUCUCCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCAC CCCCAGCGCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCU CGUAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUG UUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCU CGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA AACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUC AGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACA AGAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUC GUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCA AUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCU CAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCC GUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUC GGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAA AGAUCAUCUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCG CAACAUCUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGA AUGAAAUCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUU AUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUA AAUAUAAAAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAA UCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAU CAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCAC CCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAG AUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACC UCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAU CUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAA CCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUA AACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCAC CUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAU GAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUC AAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCC AUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUU GAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUA UCACCAUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGU AUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAA CAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGC AUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAA CUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUU UGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUA CGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCAC UGAAAACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGU ACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAA CCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCU UGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAAC CUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGC UAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCU UAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCAC AAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUG UUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCA ACACAGAGUAGUAGACACAAUAAAUGAGAAGUAAGCUUGACUCCU AUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUAUA AUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAAAG CAUUUUUUUCACUGC(A).sub.n 46 mtGFP_ UCAGAUCGCUAGCGCUACCGGUCGCCACCAUAGUGAGCAAGGGCGA s_2.7_ GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC endo GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAAGACACCACCCCGGAGAACAGCUCCU CGCUAGCUCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCC CGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGG GGAGAACGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGA GGAGCCGAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCG GUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCG CUCUUUUUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCG GCCGUACCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUC GUCUCUCCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCAC CCCCAGCGCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCU CGUAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUG UUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCU CGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUA AACAAGAGGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUC AGCUUUCCGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACA AGAGAAAACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUC GUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCA AUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCU CAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCC GUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUC GGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAA AGAUCAUCUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCG CAACAUCUUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGA AUGAAAUCACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUU AUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUA AAUAUAAAAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAA UCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAU CAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCAC CCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAG AUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACC UCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAU CUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAA CCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUA AACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCAC CUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAU GAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUC AAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCC AUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUU GAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUA UCACCAUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGU AUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAA CAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGC AUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAA CUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUU UGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUA CGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCAC UGAAAACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGU ACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAA CCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCU UGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAAC CUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGC UAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCU UAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCAC AAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUG UUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCA ACACAGAGUAGUAGACACAAUAAAUGAGAAGUAAGCUUGACUCCU AUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUAUA AUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAAAG CAUUUUUUUCACUGC(A).sub.n 47 mtGFP_ UCAGAUCGCUAGCGCUACCGGUCGCCACCAUAGUGAGCAAGGGCGA NLS_s_ GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC 2.7_endo GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGGCCGGACUCAGAUCUCGAGCUGAUCCAAAAA AGAAGAGAAAGGUAGAUCCAAAAAAGAAGAGAAAGGUAGAUCCAA AAAAGAAGAGAAAGGUAAGGAUCCACCGGAUCUAGAUAACUGUCC GGAAGACACCACCCCGGAGAACAGCUCCUCGCUAGCUCCCCAGAUC GCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCC GGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGAC UUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAA CGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUC UGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCU UUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACC CAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCC CGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACC GCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGG GGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACU CGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACA AAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCG GUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCG CAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAA CCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCA AAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAU AGAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUG CUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAA GACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAG AGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCG UCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGC CGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAA GAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACC CGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUU UCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGA CACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAAC AACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGU AGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCA CUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUG GAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUA CAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUU ACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUG CAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGU AGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAA GUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGA UGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAU ACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUC UCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCA UCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCA AAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUU CUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCA CAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAG CUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUA GUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCA CGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUU UGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUA GACACAAUAAAUGAGAAGUAAGCUUGACUCCUAUAGUGUCACCUA AAUGUCUAGAAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUA AAGCAAUAGCAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACU GC(A).sub.n 48 mtGFP_s_ UCAGAUCGCUAGCGCUACCGGUCGCCACCAUAGUGAGCAAGGGCGA endo GGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGUCGAGCUGGACGGC GACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGC GAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCG GCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUA CGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCAC GACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCA CCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGU GAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGG CAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGA GUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAG AAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAG GACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCA UCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCAC CCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUG GUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGG ACGAGCUGUACAAGUCCGGAAGACACCACCCCGGAGAACAGCUCCU CGGAUCCACCGGAUCUAGAUAACUGAUCAUAAUCAGCCAUACCACA UUUGUAGAGGUUUUACUUGCUUUAAAAAACCUCCCACACCUCCCCC UGAACCUGAAACAUAAAAUGAAUGCAAUUGUUGUUGUUAACUUGU UUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAGCAUCACAA AUUUCACAAAUAAAGCAUUUUUUUCACUGC(A).sub.n 49 Fulllength UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC 2.7 UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG RNA_endo CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA (sense) CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUCGGCGUCGGCAUGCCGCUGAUC9GCAGUGGCCCCACCUCGGCA UGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCU GUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACA AAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACA UGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCC GGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCG AUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAG CGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUU UAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAU GAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACC AUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUAC CUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUU CAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUA AUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCA GCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAG CUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGA AAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAA ACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCG UGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA AAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUUUGCAUGCAGCUUGACUC CUAUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUA UAAUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAA AGCAUUUUUUUCACUGC(A).sub.n 50 2.7RNA UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC domain UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU 2_endo CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA (sense) AAAGAAAAAAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGA AACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAGC AUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A).sub.n 51 2.7RNA UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC domain GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA 3_endo ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC (sense) CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAG AAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUAG CAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A).sub.n 52 Multimer UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC sequence UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU D2x4_endo CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUUUAUCUUCUCC UUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAA UCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGUAUCCG GUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGG AUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAAC AAGAGGGUAAAAAGAAAAACCACACCUCCACCGGUGGGCCGUUUU AUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUC UCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAG AAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUA GAAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAAUAAAGCAAUA GCAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCACUGC(A).sub.n 53 Multimer UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC sequence CCGGCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGA D3x4_endo CAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCU GCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAU CUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCC CGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGU CAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACG AAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUC GACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAU AGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCC CUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUC CUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGA AUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGA CGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUU UUACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCC GCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUGACUC CUAUAGUGUCACCUAAAUGUCUAGAAACUUGUUUAUUGCAGCUUA UAAUGGUUACAAAUAAAGCAAUAGCAUCACAAAUUUCACAAAUAA AGCAUUUUUUUCACUGC(A).sub.n 54 Multimer UCAGAUCUAAUACGACUCACUAUAGGCGCUUCCGGAAGAGCUAGC sequence CCGGCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGA D3x4_D2x4_ CAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCU endo GCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAU CUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCC CGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUC AUAGGAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGU CAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACG AAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUC GACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAU AGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCC CUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUC CUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGA AUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGC GAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAU UAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGA CGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUU UUACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCC GCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCGG AAGAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGG AUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAAC AAGAGGGUAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUU UAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUAC CUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAG AUCGUAUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCC UUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCA GAUGAUAAACAAGAGGGUAAAAAGAAAAACCACACCUCCACCGGU GGGCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAACGGCCCAAGCUUGACUCCUAUAGUGUCACC UAAAUGUCUAGAAACUUGUUUAUUGCAGCUUAUAAUGGUUACAAA UAAAGCAAUAGCAUCACAAAUUUCACAAAUAAAGCAUUUUUUUCA CUGC(A).sub.n 55 2.7core UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUCGGCGUCGGCAUGCCGCUGAUC9GCAGUGGCCCCACCUCGGCA UGCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCU GUAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACA AAAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACA UGGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCC GGCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCG AUCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAG CGUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUU UAUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAU GAAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACC AUUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUAC CUUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUU CAGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUA AUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCA GCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAG CUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGA AAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAA ACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCG UGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA AAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUUUGCAUGC 56 D1_core CAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGCGCUCG GACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUGGCCGGGA GAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGAAGGGUCG CCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUUUCUU UUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGUUUCUCUUC CGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGCACGCGUGU AUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUCAGCAGCACC ACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCGCCACCGCGUU AUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGUCGGCGGCCGGU CGGCUUCUG 57 D2_core UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA AAAGAAAAA 58 D3_core GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAAC 59 D4_core CGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCC GGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAA AAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAA GAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGA AGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCG GCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCA AUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUU GCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCC UCGC 60 D1_core UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCUUUUAUUAUUUUUUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACU CGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACA AAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCG GUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCG CAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAA CCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCA AAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAU AGAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUG CUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAA GACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAG AGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCG UCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGC CGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAA GAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACC CGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUU UCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGA CACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAAC AACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGU AGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCA CUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUG GAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUA CAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUU ACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUG CAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGU AGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAA GUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGA UGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAU ACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUC UCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCA UCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCA AAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUU CUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCA CAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAG CUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUA GUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCA CGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUU UGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUA GACACAAUAAAUGAGAAGUUUGCAUGC 61 D2_core UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUC GAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAA AAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACC GACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUC CUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCG AUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUU CCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACA AUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGG UGUAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGC AAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAAC CAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAA AACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUA GAAACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGC UCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAG ACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGA GAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGU CGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCC GGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAG AAAACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCC GAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUU CUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGAC ACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACA ACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUA GUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCAC UUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGG AAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUAC AAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUA CGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGC AAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUA GUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAG UACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAU GUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUA CUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUC CUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUC GCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAA AAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCU CGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACA AAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCU UUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGU AUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACG GAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUG UUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGA CACAAUAAAUGAGAAGUUUGCAUGC 62 D3_core UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAAGAAGAACAAAAAGAUCAUCUCUCUCGGUG UAUAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAA GACGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCA AGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAA CGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGA AACCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCC UAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACG ACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAG AGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGG CAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGG CGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAA ACAAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAG AUCAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUU GAAAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACG CUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACA UCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUC GACUCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUC UUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAA CAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAA AAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGG AUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAU CUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUA GAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUAC ACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUA CUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUC GGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCU GUCACGACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGC AACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAA AAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCG UGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAA AACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUU UCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAU AUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGA UUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUU UGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACA CAAUAAAUGAGAAGUUUGCAUGC 63 D4_core UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAG GAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCAUUUU ACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACCUUAG GUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCC AAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAG UAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCAGCAU CAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUU UAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGAAAAC AGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAAACAC ACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCGUGAC UUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAG ACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAGACAA UAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUUAGGA UCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUC UCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUC CCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGU CGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUU UUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACAGAGU AGUAGACACAAUAAAUGAGAAGUUUGCAUGC 64 2.7 GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA RNA_AS_ CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA core) AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUG ACCGACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGG ACACGGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCC AUGAGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGC GGAUUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUG UUGACGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUU UCUCUUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGA AAGCUGAGGUACCCAAAUGUCUGUAGCUUUUUUCUUUUUACCCUC UUGUUUAUCAUCUGCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAU AAUCCGAGAUUAAGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUA AUAAAACAGAAGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGC CUACGAGGAACGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCG CUGGGGGUGGCGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAG GAGAGACGAUGCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAU GGUACGGCCGGGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGA UAAAAAGAGCGGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGA AGAGAAGGACCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCA UCUCGGCUCCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCG CCGUUCUCCCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUU CGCCCGCCGGGGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGG GA 65 D1AS_core CAGAAGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGA GGAACGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGG GUGGCGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGA CGAUGCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACG GCCGGGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAA GAGCGGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAA GGACCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGG CUCCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUC UCCCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCG CCGGGGCUUCUG 66 D2AS_core UUUUUCUUUUUACCCUCUUGUUUAUCAUCUGCGAUUCGUGGUAGG UAGGAGAGGGAAAUGAUAAUCCGAGAUUAAGGAAAGGAGAAGAUA AAAAAUAAAA 67 D3AS_core GUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGACGCGUCAGGAU GUGCAGGGCAUGCGGGGAAUCAGGACCGGACACGGGAUAAUUUCA UCUACCUAUACGGAGAUCGCGGUCCUCGCCAUGAGGAUCGCGACAG GCGCGUCGAGGGGGCAGGAACACCCUUGCGGAUUGACAUUCUUGG UGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGACGAUGAGGAUAA AUAAAAAUGACC 68 D4AS_core GCGAGGAUAAAAAUGGAUGACUCCUUCGUGUCCAGGGAGUCGACU ACUGCAACGCUGAUUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUU GUUAUUGAUCGAAUCAUGGUGCAGAACGGCGACGGAGAGGAGCGU GUCCGCCGCCGGGAAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAG AAAUCUUCCAUGUGUUUAUCGUAGUGAUCGAAAUCGACUGAUCUC GGGUUCUUUUUGUUGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUU CUUUUUUUACAGAAAGAUACUUUUUUCAUGAGCAAUUCCUCGCCC GGCGCCGGCAUGCCGAGGUGGGGCCACUGCGAUCAGCGGCAUGCCG ACGCCG 69 D1AS_ GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA core CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUG ACCGACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGG ACACGGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCC AUGAGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGC GGAUUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUG UUGACGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUU UCUCUUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGA AAGCUGAGGUACCCAAAUGUCUGUAGCUUUUUUCUUUUUACCCUC UUGUUUAUCAUCUGCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAU AAUCCGAGAUUAAGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUA AUAAAAGAGAACGCCGGGGCAGCAGCGAUCUGGGGA 70 D2AS_ GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA core CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUG ACCGACGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGG ACACGGGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCC AUGAGGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGC GGAUUGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUG UUGACGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUU UCUCUUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGA AAGCUGAGGUACCCAAAUGUCUGUAGCUAAAAAUAAUAAAACAGA AGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAA CGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGG CGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAU GCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCG GGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGC GGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGAC CGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCC UCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCC CAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGG GGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGA 71 D3AS_ GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA core CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUGCGAGGAUAAAAA UGGAUGACUCCUUCGUGUCCAGGGAGUCGACUACUGCAACGCUGA UUGAUUAAAAGAUGGUCUCCGAUGAUGAUGUUGUUAUUGAUCGAA UCAUGGUGCAGAACGGCGACGGAGAGGAGCGUGUCCGCCGCCGGG AAGGUGGUCUCUUUCUCUUUUCUUUUUUCAAGAAAUCUUCCAUGU GUUUAUCGUAGUGAUCGAAAUCGACUGAUCUCGGGUUCUUUUUGU UGGUUUCUUUUCGGUUAAUCAUGUAUUGUUUUCUUUUUUUACAGA AAGAUACUUUUUUCAUGAGCAAUUCCUCGCCCGGCGCCGGCAUGCC GAGGUGGGGCCACUGCGAUCAGCGGCAUGCCGACGCCGACCCGGGG AUCUUGGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCG GGUGGCAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGA UGAUUAUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAA GAUUGGAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUA UUUAUCUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUA AUAAAAACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUC AUUCUCAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGU UGCGAUGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGA UCUUUUUGUUCUUCUUUGUUUUUGUUCUGUUUUCUCUUGUUGGGA AUCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGCUGAGGUACC CAAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGUUUAUCAUCU GCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUCCGAGAUUAA GGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUAAUAAAACAGAAGC CGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUACGAGGAACGG AUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGGGGGUGGCGG UAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGAGACGAUGCA UACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUACGGCCGGGA GACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAAAAGAGCGGU UGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAGAAGGACCGG GGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUCGGCUCCUCC AUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGUUCUCCCCAU CCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCCCGCCGGGGC UUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGA 72 D4AS_ GCAUGCAAACUUCUCAUUUAUUGUGUCUACUACUCUGUGUUGCUA core CAGGGAGUGAAGGGGGUGAAGGCAAACAAAAAAAAAAGGAACAAA AUAAUAGAUUAGCAGAAGGAAUAAUCCGUGCGACCGAGCUUGUGC UUCUUUUCUUAUAAGGAGGCAAAUAUACUAGGGAAAACUUAAGAA UAGGAAGAAACCGAGGUUUGGGAGAAAAGCUGAGAUAAAAUAGCG CAUUUUCCAUACAGAGGUUGUUGUUUUUGUGGAUCCUAAGAGGUU UCAAGUGCGAAUCUCAAAGUUCUCACGAGAAUAUUGUCUUCAAGA AUCGACAACUGUGGUCCAAGAUUUUUUUUUGGUCUUUUUAGGUUC UGCGAGGGACAUCACGAUGGAUCGUUGCGAUGAAGUCACGCGUAC GCCUCUGGUGUGGCGCGGUGUCGUGACAGGAGAGUGUGUUUUCAG UGCAGAGCUGUCUUGAUUCCUAUAUCCGAGUAUCUGUUUUCUCGU AAGGACGGUAAUCUUCUUUGGUGUAAGUACAUCUAAAAGCUGCAA ACUAUAUUUUAAGGGCUGUCUCUAGGUGUACUUUGAUGCUGGAGU UUUUCGCUGUGUUGAUGUGAAUAAAUCUACUACUACUAUUAUAUG CAGAAAGAGUGAUUAUGCCGAGACAAGAUUGCAUUGGCUGAACUG UUUCAAAAACGCCUACACUCUACUUAUCCGUAAACCUAAGGUAAU ACUAUGUGUAAGUUGUUUUUUUUUCUUUUUGUAGUAAAAUGGUGA UACGUGCAAUUAAAACUGUAUUCCAUGUUUCCAUCCUUUCAUUUC AACUUUAAAGGCGGCUUUGAGAGCGAAGAAGUACCCGGGGAUCUU GGAUUCACCGUUUUCUCUCUUCUCUCUCUACAUACAGACCGGGUGG CAGGAGCGGUAAGGAAUCAUCGUCGUCUUUCAUUCUUCGAUGAUU AUGGUAAUACUAAAUCUUAUCUAGGAGCAUAUACAUCUAAGAUUG GAGUACUAGUAGUCGUUUGUGGUUUCUAUUUUUUUUUAUAUUUAU CUAUGACAGUUUUUCUGUUUUUCGUUUUGAUAAUAAUAUAAUAAA AACUCAUGGACGUGAAAUCUGGCUUGGUUGUGGUGAUUUCAUUCU CAUUAUUGUUGUUUUCUUUCCGUCUUGCGGAUGAAGAUGUUGCGA UGCGGUUGUUGUUGGUGUUGCUAUACACCGAGAGAGAUGAUCUUU UUGUUCUUCUGGUUCAUUUCCUAUGAUUGUUUGGCUGCUGACCGA CGCGUCAGGAUGUGCAGGGCAUGCGGGGAAUCAGGACCGGACACG GGAUAAUUUCAUCUACCUAUACGGAGAUCGCGGUCCUCGCCAUGA GGAUCGCGACAGGCGCGUCGAGGGGGCAGGAACACCCUUGCGGAU UGACAUUCUUGGUGGUGUUUCGUUGUUGUCGGUAGUUGUUGUUGA CGAUGAGGAUAAAUAAAAAUGACCUUGUUUUUGUUCUGUUUUCUC UUGUUGGGAAUCGUCGACUUUGAAUUCUUCGAGUUAUCGGAAAGC UGAGGUACCCAAAUGUCUGUAGCUUUUUUCUUUUUACCCUCUUGU UUAUCAUCUGCGAUUCGUGGUAGGUAGGAGAGGGAAAUGAUAAUC CGAGAUUAAGGAAAGGAGAAGAUAAAAAAUAAAAAAAAAUAAUAA AACAGAAGCCGACCGGCCGCCGACCCGUUCCCCAGGACCAGCCUAC GAGGAACGGAUAACGCGGUGGCGACGGCAGCGGUGGUGGCGCUGG GGGUGGCGGUAGUGGUGCUGCUGAUGGUAGUCGGGACGGAGGAGA GACGAUGCAUACAUACACGCGUGCAUGCUGCAUGGGUGGAUGGUA CGGCCGGGAGACGCGGAAGAGAAACUCACAUAAAAAGGUGAUAAA AAGAGCGGUUGAAAAAAGAAAACGAGAUUCGACCAGACAGAAGAG AAGGACCGGGGCUUGGCGACCCUUCCACGACUGCCGUUGUCAUCUC GGCUCCUCCAUCUUCUCCCGGCCACGGGCGGCUAAGUCACCGCCGU UCUCCCCAUCCGUCCGAGCGCCGACCGACCAGCCGGCCGAUUCGCC CGCCGGGGCUUCUGGAGAACGCCGGGGCAGCAGCGAUCUGGGGA 73 Multimer UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU sequence CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA D2x4_core AAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGA UUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACA AGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUU AAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGA UGAUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCU CCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACG AAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA 74 Multimer GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA sequence ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC D3x4_core CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAAC UACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGU GUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGAC CGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAAGGUCAUUUUUAUUUAUCCUCAUCGUC AACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAU GGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUG UCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGU CAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAA GAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUC GCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAA AUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCU GACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACC 75 Multimer GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA sequence ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC D3x4_D2x4_ CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG core UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAAC UACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGU GUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGAC CGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAAGGUCAUUUUUAUUUAUCCUCAUCGUC AACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAU GGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUG UCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGU CAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUA UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAA GAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUC GCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAA AUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCU GACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCUUUU AUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUC UCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAG AAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAU CAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAG GGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUC UCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAU AAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUU UCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUC GCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACGGCCC 76 Multimer UUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUU sequence CCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAA D2x4_D3X4_ AAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGA core UUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCU ACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAUUU UAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCC UCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAA AGAAAAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUAC CGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUU CCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGC GAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAU UCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAAC AAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCA ACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCC GCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUG GCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGU CCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUC AGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUAU CCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAG AAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCG CGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAA UUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUG ACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCA UUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAA ACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGA CGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAG GUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCU GCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUG AACC 77 Multimer GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA sequence ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC (D3_D2)x4_ CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG core UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG GAAAUGAACCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGG AUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAAC AAGAGGGUAAAAAGAAAAAGGUCAUUUUUAUUUAUCCUCAUCGUC AACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUC CGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAU GGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUG UCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGU CAGCAGCCAAACAAUCAUAGGAAAUGAACCUUUUAUUUUUUAUCU UCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACC ACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGGUCAU UUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAA CACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGAC GCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGG UAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUG CACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGA ACCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACA ACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGG GUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGG ACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCC UGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCC AAACAAUCAUAGGAAAUGAACCUUUUAUUUUUUAUCUUCUCCUUU CCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCG CAGAUGAUAAACAAGAGGGUAAAAAGAAAAA 78 gGFP_2.7 AUGGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC core CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGUGAUCCCCAGAUCGC UGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGG CUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUU AGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACG GCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUG GUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUU UUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCG ACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUA UUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGA AGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAA ACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGAC AACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUG CCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGA CGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAG CCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACG AAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAA CCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUA GAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGAC GAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAG AAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCA UGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCG AGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAAC AAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAU CAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGA AAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUC CUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCA UCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGAC UCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCU AGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUA CACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAU AUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCAC GACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGA UCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAA UCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAG AACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACA ACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUC CCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUU UGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUA UUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGC CUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGU 79 gGFP_s_2.7_ AUGGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC core CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGUGAUCCCCAGAUCGC UGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGG CUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUU AGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACG GCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUG GUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUU UUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCG ACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUA UUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGA AGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAA ACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGAC AACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUG CCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGA CGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAG CCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACG AAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAA CCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUA GAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGAC GAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAG AAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCA UGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCG AGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAAC AAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAU CAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGA AAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUC CUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCA UCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGAC UCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCU AGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUA CACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAU AUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCAC GACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGA UCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAA UCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAG AACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACA ACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUC CCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUU UGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUA UUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGC CUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGU 80 mtGFP_s_2.7_ AUAGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC core CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGAGAUCCCCAGAUCGC UGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGG CUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAACGGCGGUGACUU AGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCCGAGAUGACAACG GCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUG GUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUUUUAUCACCUUU UUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUACCAUCCACCCA UGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCG ACUACCAUCAGCAGCACCACUACCGCCACCCCCAGCGCCACCACCGC UGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGG AACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUUAUUUUUUUUUA UUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCU CCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGA AAAAAGCUACAGACAUUUGGGUACCUCAGCUUUCCGAUAACUCGA AGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAAACAGAACAAAA ACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGAC AACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUG CCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUC UCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCC GCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCA UAGGAAAUGAACCAGAAGAACAAAAAGAUCAUCUCUCUCGGUGUA UAGCAACACCAACAACAACCGCAUCGCAACAUCUUCAUCCGCAAGA CGGAAAGAAAACAACAAUAAUGAGAAUGAAAUCACCACAACCAAG CCAGAUUUCACGUCCAUGAGUUUUUAUUAUAUUAUUAUCAAAACG AAAAACAGAAAAACUGUCAUAGAUAAAUAUAAAAAAAAAUAGAAA CCACAAACGACUACUAGUACUCCAAUCUUAGAUGUAUAUGCUCCUA GAUAAGAUUUAGUAUUACCAUAAUCAUCGAAGAAUGAAAGACGAC GAUGAUUCCUUACCGCUCCUGCCACCCGGUCUGUAUGUAGAGAGAG AAGAGAGAAAACGGUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCA UGCCGCUGAUCGCAGUGGCCCCACCUCGGCAUGCCGGCGCCGGGCG AGGAAUUGCUCAUGAAAAAAGUAUCUUUCUGUAAAAAAAGAAAAC AAUACAUGAUUAACCGAAAAGAAACCAACAAAAAGAACCCGAGAU CAGUCGAUUUCGAUCACUACGAUAAACACAUGGAAGAUUUCUUGA AAAAAGAAAAGAGAAAGAGACCACCUUCCCGGCGGCGGACACGCUC CUCUCCGUCGCCGUUCUGCACCAUGAUUCGAUCAAUAACAACAUCA UCAUCGGAGACCAUCUUUUAAUCAAUCAGCGUUGCAGUAGUCGAC UCCCUGGACACGAAGGAGUCAUCCAUUUUUAUCCUCGCACUUCUUC GCUCUCAAAGCCGCCUUUAAAGUUGAAAUGAAAGGAUGGAAACAU GGAAUACAGUUUUAAUUGCACGUAUCACCAUUUUACUACAAAAAG AAAAAAAAACAACUUACACAUAGUAUUACCUUAGGUUUACGGAUA AGUAGAGUGUAGGCGUUUUUGAAACAGUUCAGCCAAUGCAAUCUU GUCUCGGCAUAAUCACUCUUUCUGCAUAUAAUAGUAGUAGUAGAU UUAUUCACAUCAACACAGCGAAAAACUCCAGCAUCAAAGUACACCU AGAGACAGCCCUUAAAAUAUAGUUUGCAGCUUUUAGAUGUACUUA CACCAAAGAAGAUUACCGUCCUUACGAGAAAACAGAUACUCGGAU AUAGGAAUCAAGACAGCUCUGCACUGAAAACACACUCUCCUGUCAC GACACCGCGCCACACCAGAGGCGUACGCGUGACUUCAUCGCAACGA UCCAUCGUGAUGUCCCUCGCAGAACCUAAAAAGACCAAAAAAAAA UCUUGGACCACAGUUGUCGAUUCUUGAAGACAAUAUUCUCGUGAG AACUUUGAGAUUCGCACUUGAAACCUCUUAGGAUCCACAAAAACA ACAACCUCUGUAUGGAAAAUGCGCUAUUUUAUCUCAGCUUUUCUC CCAAACCUCGGUUUCUUCCUAUUCUUAAGUUUUCCCUAGUAUAUU UGCCUCCUUAUAAGAAAAGAAGCACAAGCUCGGUCGCACGGAUUA UUCCUUCUGCUAAUCUAUUAUUUUGUUCCUUUUUUUUUUGUUUGC CUUCACCCCCUUCACUCCCUGUAGCAACACAGAGUAGUAGACACAA UAAAUGAGAAGU 81 mtGFP_s_ AUAGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUC core CUGGUCGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUG UCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGA AGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCU CGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCC GACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAG GCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUA CAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAAC CGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCC UGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUA UCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGA UCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUA CCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGAC AACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACG AGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGG GAUCACUCUCGGCAUGGACGAGCUGUACAAGAGA 82 asATP6_s6_ AGUAGAAUUAGAAUUGUGAAGAUGAUAAGUGUAGAGGGAAGGUUA 2.7_core AUGGUUGAUAUUGCUAGGGUGGCGCUUCCAAUUAGGUGCGUGAGU AGGUGGCCUGCAGUAAUGUUAUCCCCAGAUCGCUGCUGCCCCGGCG UUCUCCAGAAGCCCCGGCGGGCGAAUCGGCCGGCUGGUCGGUCGGC GCUCGGACGGAUGGGGAGAACGGCGGUGACUUAGCCGCCCGUGGCC GGGAGAAGAUGGAGGAGCCGAGAUGACAACGGCAGUCGUGGAAGG GUCGCCAAGCCCCGGUCCUUCUCUUCUGUCUGGUCGAAUCUCGUUU UCUUUUUUCAACCGCUCUUUUUAUCACCUUUUUAUGUGAGUUUCU CUUCCGCGUCUCCCGGCCGUACCAUCCACCCAUGCAGCAUGCACGC GUGUAUGUAUGCAUCGUCUCUCCUCCGUCCCGACUACCAUCAGCAG CACCACUACCGCCACCCCCAGCGCCACCACCGCUGCCGUCGCCACCG CGUUAUCCGUUCCUCGUAGGCUGGUCCUGGGGAACGGGUCGGCGGC CGGUCGGCUUCUGUUUUAUUAUUUUUUUUUAUUUUUUAUCUUCUC CUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGA AUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAAGCUACAGAC AUUUGGGUACCUCAGCUUUCCGAUAACUCGAAGAAUUCAAAGUCG ACGAUUCCCAACAAGAGAAAACAGAACAAAAACAAGGUCAUUUUU AUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACC ACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGC CUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGA UGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACA UCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCA GAAGAACAAAAAGAUCAUCUCUCUCGGUGUAUAGCAACACCAACA ACAACCGCAUCGCAACAUCUUCAUCCGCAAGACGGAAAGAAAACAA CAAUAAUGAGAAUGAAAUCACCACAACCAAGCCAGAUUUCACGUCC AUGAGUUUUUAUUAUAUUAUUAUCAAAACGAAAAACAGAAAAACU GUCAUAGAUAAAUAUAAAAAAAAAUAGAAACCACAAACGACUACU AGUACUCCAAUCUUAGAUGUAUAUGCUCCUAGAUAAGAUUUAGUA UUACCAUAAUCAUCGAAGAAUGAAAGACGACGAUGAUUCCUUACC GCUCCUGCCACCCGGUCUGUAUGUAGAGAGAGAAGAGAGAAAACG GUGAAUCCAAGAUCCCCGGGUCGGCGUCGGCAUGCCGCUGAUCGCA GUGGCCCCACCUCGGCAUGCCGGCGCCGGGCGAGGAAUUGCUCAUG AAAAAAGUAUCUUUCUGUAAAAAAAGAAAACAAUACAUGAUUAAC CGAAAAGAAACCAACAAAAAGAACCCGAGAUCAGUCGAUUUCGAU CACUACGAUAAACACAUGGAAGAUUUCUUGAAAAAAGAAAAGAGA AAGAGACCACCUUCCCGGCGGCGGACACGCUCCUCUCCGUCGCCGU UCUGCACCAUGAUUCGAUCAAUAACAACAUCAUCAUCGGAGACCAU CUUUUAAUCAAUCAGCGUUGCAGUAGUCGACUCCCUGGACACGAA GGAGUCAUCCAUUUUUAUCCUCGCACUUCUUCGCUCUCAAAGCCGC CUUUAAAGUUGAAAUGAAAGGAUGGAAACAUGGAAUACAGUUUUA AUUGCACGUAUCACCAUUUUACUACAAAAAGAAAAAAAAACAACU UACACAUAGUAUUACCUUAGGUUUACGGAUAAGUAGAGUGUAGGC GUUUUUGAAACAGUUCAGCCAAUGCAAUCUUGUCUCGGCAUAAUC ACUCUUUCUGCAUAUAAUAGUAGUAGUAGAUUUAUUCACAUCAAC ACAGCGAAAAACUCCAGCAUCAAAGUACACCUAGAGACAGCCCUUA AAAUAUAGUUUGCAGCUUUUAGAUGUACUUACACCAAAGAAGAUU ACCGUCCUUACGAGAAAACAGAUACUCGGAUAUAGGAAUCAAGAC AGCUCUGCACUGAAAACACACUCUCCUGUCACGACACCGCGCCACA CCAGAGGCGUACGCGUGACUUCAUCGCAACGAUCCAUCGUGAUGUC CCUCGCAGAACCUAAAAAGACCAAAAAAAAAUCUUGGACCACAGU UGUCGAUUCUUGAAGACAAUAUUCUCGUGAGAACUUUGAGAUUCG CACUUGAAACCUCUUAGGAUCCACAAAAACAACAACCUCUGUAUGG AAAAUGCGCUAUUUUAUCUCAGCUUUUCUCCCAAACCUCGGUUUCU UCCUAUUCUUAAGUUUUCCCUAGUAUAUUUGCCUCCUUAUAAGAA AAGAAGCACAAGCUCGGUCGCACGGAUUAUUCCUUCUGCUAAUCU AUUAUUUUGUUCCUUUUUUUUUUGUUUGCCUUCACCCCCUUCACUC CCUGUAGCAACACAGAGUAGUAGACACAAUAAAUGAGAAGU 83 2.7_s8_as UCCCCAGAUCGCUGCUGCCCCGGCGUUCUCCAGAAGCCCCGGCGGG ATP8_core CGAAUCGGCCGGCUGGUCGGUCGGCGCUCGGACGGAUGGGGAGAA CGGCGGUGACUUAGCCGCCCGUGGCCGGGAGAAGAUGGAGGAGCC GAGAUGACAACGGCAGUCGUGGAAGGGUCGCCAAGCCCCGGUCCUU CUCUUCUGUCUGGUCGAAUCUCGUUUUCUUUUUUCAACCGCUCUUU UUAUCACCUUUUUAUGUGAGUUUCUCUUCCGCGUCUCCCGGCCGUA CCAUCCACCCAUGCAGCAUGCACGCGUGUAUGUAUGCAUCGUCUCU CCUCCGUCCCGACUACCAUCAGCAGCACCACUACCGCCACCCCCAGC GCCACCACCGCUGCCGUCGCCACCGCGUUAUCCGUUCCUCGUAGGC UGGUCCUGGGGAACGGGUCGGCGGCCGGUCGGCUUCUGUUUUAUU AUUUUUUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUA UCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGA GGGUAAAAAGAAAAAAGCUACAGACAUUUGGGUACCUCAGCUUUC CGAUAACUCGAAGAAUUCAAAGUCGACGAUUCCCAACAAGAGAAA ACAGAACAAAAACAAGGUCAUUUUUAUUUAUCCUCAUCGUCAACA ACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCA AGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCG AGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCG GUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGC AGCCAAACAAUCAUAGGAAAUGAACCAGAAGAACAAAAAGAUCAU CUCUCUCGGUGUAUAGCAACACCAACAACAACCGCAUCGCAACAUC UUCAUCCGCAAGACGGAAAGAAAACAACAAUAAUGAGAAUGAAAU CACCACAACCAAGCCAGAUUUCACGUCCAUGAGUUUUUAUUAUAU UAUUAUCAAAACGAAAAACAGAAAAACUGUCAUAGAUAAAUAUAA AAAAAAAUAGAAACCACAAACGACUACUAGUACUCCAAUCUUAGA UGUAUAUGCUCCUAGAUAAGAUUUAGUAUUACCAUAAUCAUCGAA GAAUGAAAGACGACGAUGAUUCCUUACCGCUCCUGCCACCCGGUCU GUAUGUAGAGAGAGAAGAGAGAAAACGGUGAAUCCAAGAUCCCCG GGUCGGCGUCGGCAUGCCGCUGAUCGCAGUGGCCCCACCUCGGCAU GCCGGCGCCGGGCGAGGAAUUGCUCAUGAAAAAAGUAUCUUUCUG UAAAAAAAGAAAACAAUACAUGAUUAACCGAAAAGAAACCAACAA AAAGAACCCGAGAUCAGUCGAUUUCGAUCACUACGAUAAACACAU GGAAGAUUUCUUGAAAAAAGAAAAGAGAAAGAGACCACCUUCCCG GCGGCGGACACGCUCCUCUCCGUCGCCGUUCUGCACCAUGAUUCGA UCAAUAACAACAUCAUCAUCGGAGACCAUCUUUUAAUCAAUCAGC GUUGCAGUAGUCGACUCCCUGGACACGAAGGAGUCAUCCAUUUUU AUCCUCGCACUUCUUCGCUCUCAAAGCCGCCUUUAAAGUUGAAAUG AAAGGAUGGAAACAUGGAAUACAGUUUUAAUUGCACGUAUCACCA UUUUACUACAAAAAGAAAAAAAAACAACUUACACAUAGUAUUACC UUAGGUUUACGGAUAAGUAGAGUGUAGGCGUUUUUGAAACAGUUC AGCCAAUGCAAUCUUGUCUCGGCAUAAUCACUCUUUCUGCAUAUA AUAGUAGUAGUAGAUUUAUUCACAUCAACACAGCGAAAAACUCCA GCAUCAAAGUACACCUAGAGACAGCCCUUAAAAUAUAGUUUGCAG CUUUUAGAUGUACUUACACCAAAGAAGAUUACCGUCCUUACGAGA AAACAGAUACUCGGAUAUAGGAAUCAAGACAGCUCUGCACUGAAA ACACACUCUCCUGUCACGACACCGCGCCACACCAGAGGCGUACGCG UGACUUCAUCGCAACGAUCCAUCGUGAUGUCCCUCGCAGAACCUAA AAAGACCAAAAAAAAAUCUUGGACCACAGUUGUCGAUUCUUGAAG ACAAUAUUCUCGUGAGAACUUUGAGAUUCGCACUUGAAACCUCUU AGGAUCCACAAAAACAACAACCUCUGUAUGGAAAAUGCGCUAUUU UAUCUCAGCUUUUCUCCCAAACCUCGGUUUCUUCCUAUUCUUAAGU UUUCCCUAGUAUAUUUGCCUCCUUAUAAGAAAAGAAGCACAAGCU CGGUCGCACGGAUUAUUCCUUCUGCUAAUCUAUUAUUUUGUUCCU UUUUUUUUUGUUUGCCUUCACCCCCUUCACUCCCUGUAGCAACACA GAGUAGUAGACACAAUAAAUGAGAAGUUUUCGUUCAUUUUGGUUC UCAGGGUUUGUUAUAAUUUUUUAUUUUUAUGGGCUUUGGUGAGGG AGGUAGGUGGUAGUUUGUGUUUAAUAUUUUUAGUUGGGUGAUGA 84 ATP6_D3.sub.4_ AGUAGAAUUAGAAUUGUGAAGAUGAUAAGUGUAGAGGGAAGGUUA D2.sub.4_(core) AUGGUUGAUAUUGCUAGGGUGGCGCUUCCAAUUAGGUGCGUGAGU AGGUGGCCUGCAGUAAUGUUGGUCAUUUUUAUUUAUCCUCAUCGU CAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAU CCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCA UGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGU GUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGG UCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUU AUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCA AGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGU CGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGA AAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCC UGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGU CAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACG AAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUC GACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAU AGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCC CUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAA UGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCG ACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCC UGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGA UCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUC CCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAA UCAUAGGAAAUGAACCUUUUAUUUUUUAUCUUCUCCUUUCCUUAA UCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUG AUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCC UUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAA UCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUU AUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAUU UUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCC CUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAA AAGAAAAA 85 invitro GGCGCUUCCGGAAGAAAGCGCCAGUAGAAUUAGAAUUGUGAAGAU transcribed GAUAAGUGUAGAGGGAAGGUUAAUGGUUGAUAUUGCUAGGGGGGC ATP6_(D3).sub.4_ GCUUCCAAUUAGGUGCAUGAGUAGGUGGCCUGCAGUAAUGUUAAA (D2).sub.4 GCAAGGGCCUUAUUCAUGGGCUAGCCCGGCGGUCAUUUUUAUUUA RNAwith UCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACCAA indicated5 GAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUC end,3 end, GCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAA domains AUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCU D3andD2. GACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGCCGG andspacers GAAGCGCCGAAUUCAUAUCGAUCGGUCAUUUUUAUUUAUCCUCAU CGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUC AAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCC UCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCC CGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGU CGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGAUCGAAUAAA GGUACCUGUGGGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAA CUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGG UGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGA CCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAACCCCACAUUUUACCGGUAAUACCGGG GGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAAC AACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCC CCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCC GUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGC AUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUA GGAAAUGAACCCCCCGGAAGCUUUCCGGAAGAGCUAGCUUUUAUU UUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCC UACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAA AAAGCGCGAAUUCCGAUCUUUUAUUUUUUAUCUUCUCCUUUCCUU AAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGA UGAUAAACAAGAGGGUAAAAAGAAAAAGAUCGUAUCCGGUACCUG UGGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCA UUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGG UAAAAAGAAAAACCACACCUCCACCGGUGGGCCGUUUUAUUUUUU AUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACC UACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAACG GCCCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAUACUA AGGGAGUCUUGC 86 Multimer GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA (D3).sub.4_(D2).sub.4 ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC RNA CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG including UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA domains UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG D3andD2 GAAAUGAACCGCCGGGAAGCGCCGAAUUCAUAUCGAUCGGUCAUU andspacers UUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAAC ACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACG CGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGU AGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGC ACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGA ACCGAUCGAAUAAAGGUACCUGUGGGGUCAUUUUUAUUUAUCCUC AUCGUCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUG UCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAU CCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAU CCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGC GUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCCCACAUUUU ACCGGUAAUACCGGGGGGUCAUUUUUAUUUAUCCUCAUCGUCAAC AACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGC AAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGC GAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCC GGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAG CAGCCAAACAAUCAUAGGAAAUGAACCCCCCGGAAGCUUUCCGGAA GAGCUAGCUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAU UAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAA GAGGGUAAAAAGAAAAAAGCGCGAAUUCCGAUCUUUUAUUUUUUA UCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCU ACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAAGAU CGUAUCCGGUACCUGUGGUUUUAUUUUUUAUCUUCUCCUUUCCUU AAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGA UGAUAAACAAGAGGGUAAAAAGAAAAACCACACCUCCACCGGUGG GCCGUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUC AUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGG GUAAAAAGAAAAA 87 Multimer GGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAACUACCGACAACA (D3).sub.4_(D2).sub.4 ACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCC RNAcore CUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCG only UAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCA including UGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCAAACAAUCAUAG domains GAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCGUCAACAACAAC D3andD2 UACCGACAACAACGAAACACCACCAAGAAUGUCAAUCCGCAAGGGU butwithout GUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUCAUGGCGAGGAC anyspacers CGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCGUGUCCGGUCCU GAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCGGUCAGCAGCCA AACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUUUAUCCUCAUCG UCAACAACAACUACCGACAACAACGAAACACCACCAAGAAUGUCAA UCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUGUCGCGAUCCUC AUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUGAAAUUAUCCCG UGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUCCUGACGCGUCG GUCAGCAGCCAAACAAUCAUAGGAAAUGAACCGGUCAUUUUUAUU UAUCCUCAUCGUCAACAACAACUACCGACAACAACGAAACACCACC AAGAAUGUCAAUCCGCAAGGGUGUUCCUGCCCCCUCGACGCGCCUG UCGCGAUCCUCAUGGCGAGGACCGCGAUCUCCGUAUAGGUAGAUG AAAUUAUCCCGUGUCCGGUCCUGAUUCCCCGCAUGCCCUGCACAUC CUGACGCGUCGGUCAGCAGCCAAACAAUCAUAGGAAAUGAACCUU UUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAUUAUCAUUUCC CUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAAGAGGGUAAA AAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUAAUCUCGGAU UAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAUGAUAAACAA GAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUCCUUUCCUUA AUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGAAUCGCAGAU GAUAAACAAGAGGGUAAAAAGAAAAAUUUUAUUUUUUAUCUUCUC CUUUCCUUAAUCUCGGAUUAUCAUUUCCCUCUCCUACCUACCACGA AUCGCAGAUGAUAAACAAGAGGGUAAAAAGAAAAA
The foregoing sequences are further understood by reference to the following explanation of colour codes that are additionally set forth along with the colour-shaded sequences in the international publication no. WO 2017/192102 Al, dated Nov. 9, 2017, for international application no. PCT/SG2017/050238, filed May 8, 2017, of which this application is the U.S. national stage.
TABLE-US-00005 Colourcodesforsequences1to84 Domain1;Domain2;Domain3;Domain4 UCAGAUC:Last7basesofCMVpromoter; GGCGCU:last6basesofT7promoter GGAGUC:Last6basesofSP6promoter AUG:Genomicstartcodon; UGA:GenomicstopcodonUCCGGA(Sequenceonly: UCCGGA): BspEIrestrictionsite; GCUAGC: NheIrestrictionsite ACCACCCCGGAGAACAGCUCCUC:spacerstabilizingGFP structure AUA:mitochondriaspecificstartcodon; AGA:mitochondriaspecificstopcodon GAAUUC:EcoRIrestrictionsite; ACCGGU:AgeIrestrictionsite AAGCUU:HindIIIrestrictionsite; UCUAGA:XbaIrestrictionsite UCCGGA:BspEIrestrictionsite; AAUAAA:PolyAcleavagesite CCGGC:S1a; GCCGG:S1b CGAUC:S2a; GAUCG:S2b UGUGG:S3a; CCACA:S3b CCGGGG:S4a; CCCCGG:S4b AAGCAAGGGUUAUUCCGAAUUGG:S6a; CCAAUUCGGAAUAACCC:S6b GGUUGGAUUGGGG:S8a; CCCCAAACCAACCUCUACCGGAAGCGCCUUUU:S8b AntisenseAP8;AntisenseATP6 ColourcodesforSEQIDNOs:85to87 ATP6antisenseRNA 4DomainsD3(separatedbyspacers) 4DomainsD2(separatedbyspacers) Promoter-derivedsequence GGCGCUUCCGGAAGAAAGCGCC ATP6-(D3x4_D2x4)spacer: AAAGCAAGGGCCUUAUUCAUGGGCUAGCCCGGC D3spacer1: GCCGGGAAGCGCCGAAUUCAUAUCGAUC D3spacer2: GAUCGAAUAAAGGUACCUGUGG D3spacer3: CCACAUUUUACCGGUAAUACCGGGG (CCACAUUUUACCGGUAAUACCGGGG) D3x4-D2x4spacer:CCCCGGAAGCUUUCCGGAAGAGCUAGC (CCCCGGAAGCUUUCCGGAAGAGCUAGC) D2spacer1: AGCGCGAAUUCCGAUC(AGCGCGAAUUCCGAUC) D2spacer2: GAUCGUAUCCGGUACCUGUGG(GAUCGUAUCCGGUACCUGUGG) D2spacer3: CCACACCUCCACCGGUGGGCCG(CCACACCUCCACCGGUGGGCCG) RNA3 endincludingpolyadenylationsignal: CGGCCCAAGCUUGACUCCUAUAGUGUCACCUAAAUGUCUAGAUACUAAG GGAGUCUUGC